

5 METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASES ASSOCIATED WITH  
ABERRANT MICROSATELLITE EXPANSION

10 BY

Maurice S. Swanson

Rahul N. Kanadia

15 And

Charles A. Thornton

## RELATED APPLICATIONS/PATENTS & INCORPORATION BY REFERENCE

This application claims priority to U.S. Provisional Application Serial No. 60/551,748, filed on March 10, 2004 as Attorney Docket No. 49163.60677, the contents of which is incorporated herein by reference.

Each of the applications and patents cited in this text, as well as each document or reference cited in each of the applications and patents (including during the prosecution of each issued patent; "application cited documents"), and each of the PCT and foreign applications or patents corresponding to and/or claiming priority from any of these applications and patents, and each of the documents cited or referenced in each of the application cited documents, are hereby expressly incorporated herein by reference, and may be employed in the practice of the invention. More generally, documents or references are cited in this text, either in a Reference List before the claims, or in the text itself; and, each of these documents or references ("herein cited references"), as well as each document or reference cited in each of the herein cited references (including any manufacturer's specifications, instructions, etc.), is hereby expressly incorporated herein by reference.

## STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH

This work was supported in part by a grant from the National Institutes of Health (U54-NS48843). The United States Government may have certain rights to the invention.

## BACKGROUND OF THE INVENTION

### Microsatellite Expansion Diseases

Aberrant expansion of microsatellites in DNA is associated with a number of neurological and neuromuscular diseases (O'Donnell, WT, Warren, ST (2002), *Annu. Rev. Neurosci.* **25**: 315). These diseases are caused by microsatellite repeat expansions in coding and non-coding regions. The characterized coding region expansion diseases include Dentatorubral pallidoluysian atrophy (DRPLA), Huntington chorea (HD), Oculopharyngeal muscular dystrophy (OPMD), Spinobulbar muscular atrophy (SBMA), and Spinocerebellar ataxia types 1, 2, 3, 6, 7, and 17 (SCA1, SCA2, SCA3, SCA6, SCA7, SCA17). The characterized non-coding region expansion diseases include Fragile XA, Fragile XE, Friedrich's ataxia, Myotonic Dystrophy type 1 (DM1), Myotonic Dystrophy type 2 (DM2), and Spinocerebellar ataxia types 8, 10, and 12 (SCA8, SCA10, SCA12). Huntington's disease-like type 2 (HDL2) is likewise caused by a microsatellite expansion.

Microsatellite expansion diseases have been most commonly associated with trinucleotide expansion mutations. In fact, at least 16 of the microsatellite expansion diseases reported to date have been characterized as trinucleotide expansion diseases. More recently, however, microsatellite expansion

diseases have also been associated with tetranucleotide and even pentanucleotide expansion mutations.

Disease severity and age of onset have both been related to the size of the expansion mutation, eventually leading to muscle weakness and premature cataract formation, and, in severe cases, to hypotonia, muscle heart block, and nervous system dysfunction (Korade-Mirmics, Z, Babitzke, P, Hoffman, E (1998) *Nuc.*

5 *Acids Res.* **26(6)**: 1363-1368).

Myotonic dystrophy (dystrophia myotonica, DM) is a multisystemic, dominantly inherited disorder often characterized by myotonia, or, delayed muscle relaxation due to repetitive action potentials in myofibers, and muscle degeneration. Manifestations of DM may also include heart block, ocular cataracts, hypogonadism, and nervous system dysfunction.

10 Myotonic dystrophy type 1 (DM1) is caused by a trinucleotide (CTG)<sub>n</sub> expansion (n=50 to >3000) in the 3'-untranslated region (3'UTR) of the *Dystrophia myotonica-protein kinase (DMPK)* gene. Myotonic dystrophy type 2 (DM2) is caused by a tetranucleotide (CCTG)<sub>n</sub> expansion (n=75 to ~11,000) in the first intron of *zinc finger protein 9 (ZNF9)* gene (Ranum, LPW, Day, JW (2002) *Curr. Opin. in Genet. and Dev.* **12**:266-271).

15 Although the expansions are located on different chromosomes, there appears to be a common pathogenic mechanism involving the accumulation of transcripts into discrete nuclear RNA foci containing long tracts of CUG or CCUG repeats expressed from the expanded allele (Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LP (2001), *Science* **293**: 864–867).

In effect, both DM1 and DM2 mutant transcripts accumulate as foci within muscle nuclei  
20 (Liquori, *et al.*, 2001). An indication that these transcripts are pathogenic comes from studies on *HSA<sup>LR</sup>* mice, which express a large CTG repeat in the 3'-UTR of a human skeletal actin transgene (Mankodi, A, Logigian, E, Callahan, L, McClain, C, White, R, Henderson, D, Krym, M, Thornton, CA ( 2000) *Science* **289**: 1769-1773). These transgenic mice develop myonuclear RNA foci, myotonia, and degenerative muscle changes similar to those seen in human DM. The myotonia in *HSA<sup>LR</sup>* mice is caused by loss of  
25 skeletal muscle chloride (ClC-1) channels due to aberrant pre-mRNA splicing (Mankodi, A, Takahashi, MP, Jiang, H, Beck, CL, Bowers, WJ, Moxley, RT, Cannon, SC, Thornton, CA ( 2002) *Mol. Cell* **10**: 35-44). Similar ClC-1 splicing defects exist in DM1 and DM2. However, the connection between accumulation of mutant DM transcripts in the nucleus and altered splice site selection has not been established (Faustino, NA, Cooper, TA (2003) *Genes Dev.* **17**: 419-437).

30 The RNA gain-of-function hypothesis proposes that mutant DM transcripts alter the function and localization of alternative splicing regulators, which are critical for normal RNA processing. Consistent with this proposal, misregulated alternative splicing in DM1 has been demonstrated for six pre-mRNAs: cardiac troponin T (cTNT), insulin receptor (IR), muscle-specific chloride channel (ClC-1), tau, myotubularin-related protein 1 (MTMR1) and fast skeletal troponin T (TNNT3) (Kanadia RN, Johnstone

KA, Mankodi A, Lungu C, Thornton CA, Esson D, Timmers AM, Hauswirth WW, Swanson MS (2003), *Science* **302**: 1978–1980).

In all cases, normal mRNA splice variants are produced, but the normal developmental splicing pattern is disrupted, resulting in expression of fetal protein isoforms that are inappropriate for adult tissues. The insulin resistance and myotonia observed in DM1 correlate with the disruption of splicing of two pre-mRNA targets, IR and CIC-1, respectively (Savkur RS, Philips AV, Cooper TA, Dalton JC, Moseley ML, Ranum LP, Day JW (2004), *Am J Hum Genet* **74**: 1309–1313).

The mechanism by which expanded repeats alter the regulation of pre-mRNA alternative splicing is unclear. Two families of RNA-binding proteins have been implicated in DM1 pathogenesis: CUG-BP1 and ETR-3-like factors (CELF) and muscleblind-like (MBNL) proteins (Ladd AN, Charlet-B N, Cooper TA (2001), *Mol Cell Biol* **21**: 1285–1296). Six CELF (also called BRUNOL) genes have been identified in humans (Ladd AN, Nguyen NH, Malhotra K, Cooper TA (2004), *J Biol Chem* **279**: 17756–17764). All six CELF proteins have been shown to regulate pre-mRNA alternative splicing and two (CUG-BP1 and ETR-3/CUG-BP2) have been shown to have cytoplasmic RNA-associated functions (Mukhopadhyay D, Houchen CW, Kennedy S, Dieckgraefe BK, Anant S (2003), *Mol Cell* **11**: 113–126).

A functional link has been established between splicing regulation by CELF proteins and DM1 pathogenesis. CUG-BP1 regulates alternative splicing of at least three of the pre-mRNAs (cTNT, IR and CIC-1) that are misregulated in DM striated muscle (Charlet-B N, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA (2002b), *Mol Cell* **10**: 45–53). The splicing patterns observed for all three pre-mRNAs are consistent with increased CUG-BP1 activity and an increase in CUG-BP1 steady-state levels in DM1 striated muscle (Charlet-B N, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA (2002b), *Mol Cell* **10**: 45–53).

Furthermore, cTNT minigenes expressed in DM1 muscle cultures or cTNT and IR pre-mRNAs co-expressed with CUG repeat RNA in normal cells reproduce the aberrant splicing patterns observed for endogenous genes in DM cells (Philips AV, Timchenko LT, Cooper TA (1998), *Science* **280**: 737–741; Savkur RS, Philips AV, Cooper TA (2001), *Nat Genet* **29**: 40–47). The *trans*-dominant effects of endogenous or co-expressed CUG repeat RNA on cTNT and IR splicing regulation require the intronic CUG-BP1-binding sites, indicating that binding by CUG-BP1 and/or other CELF family members to their cognate intronic regulatory elements is required for induction of aberrant splicing regulation by CUG repeat RNA (Philips AV, Timchenko LT, Cooper TA (1998), *Science* **280**: 737–741; Savkur RS, Philips AV, Cooper TA (2001), *Nat Genet* **29**: 40–47).

The CNS symptoms of DM1 may include cognitive impairment, hypersomnolence, heightened sensitivity to anesthetic agents, central hypoventilation, neuroendocrine dysfunction, and effects on personality and behavior [reviewed by Harper (Harper, P.S. (2001), *Myotonic dystrophy*. Saunders London) and Ashizawa (Ashizawa, T. (1998), *Arch. Neurol.*, **55**, 291-293)]. Some of these effects, such

as, mental retardation in individuals with congenital DM1, occur during development (Dyken, P.R., Harper, P.S. (1973), *Neurology*, 23, 465-473). Other symptoms, such as, hypersomnolence, appear during adult life. The mechanism and neuropathologic correlates for CNS involvement in DM1 are unknown.

5 It is presently unclear whether any steps in the pathogenic sequence of poly(CUG) expression, formation of RNA inclusions, sequestration of RNA binding proteins, and disruption of alternative splicing can take place in the CNS. There is controversy about which cells in the mature brain, if any, express DMPK (Lam, L.T., Pham, Y.C., Nguyen, T.M., and Morris, G.E. (2000), *Hum. Mol. Genet.*, 9, 2167-2173).

10 Microtubule-associated protein tau (MAPT) pre-mRNA is alternatively spliced at exons 2, 3, and 10 (Goedert, M., Spillantini, M.G., Jakes, R., Rutherford, D., and Crowther, R.A. (1989), *Neuron*, 3, 519-526). Tau transcripts in fetal brain do not include exon 10, whereas ~50% of transcripts in adult brain include this exon which encodes an additional microtubule binding domain (Hong, M., Zhukareva, V., Vogelsberg-Ragaglia, V., Wszokek, Z., Reed, L., Miller, B.I., Geschwind, D.H., Bird, T.D., McKeel, D.,  
15 Goate, A. et al. (1998), *Science*, 282, 1914-1917). Alternative splicing of exons 2 and 3 also is developmentally regulated (neither exon is included in the fetus, adults mainly include exon 2).

The relative proportion of tau splice products is tightly regulated, as shown by kindreds with frontotemporal dementia and parkinsonism (FTDP-17) due to mutations in MAPT. Silent mutations in MAPT exon 10, or, in the flanking intron, lead to FTDP-17 by disrupting *cis* elements that regulate splicing  
20 of tau pre-mRNA (D'Souza, I., Poorkaj, P., Hong, M., Nochlin, D., Lee, V.M., Bird, T.D., and Schellenberg, G.D. (1999), *Proc. Natl. Acad. Sci. U.S.A.*, 96, 5598-5603). Usually these mutations lead to increased inclusion of exon 10 (Lee, V.M., Goedert, M., and Trojanowski, J.Q. (2001), *Annu. Rev. Neurosci.*, 24, 1121-1159). However, some MAPT mutations that segregate with FTDP-17 have the opposite effect of reducing exon 10 inclusion (Stanford, P.M., Shepherd, C.E., Halliday, G.M., Brooks, W.S.,  
25 Schofield, P.W., Brodaty, H., Martins, R.N., Kwok, J.B., and Schofield, P.R. (2003), *Brain*, 126, 814-826).

RNA-binding proteins that regulate alternative splicing bind to sequence-specific elements in the pre-mRNA to enhance or repress inclusion of alternative exons. Aberrant regulation of alternative splicing can cause the expression of inappropriate splicing patterns leading to human disease (Faustino and Cooper, 2003). Myotonic dystrophy constitutes an example of a disease that alters the function of RNA-binding proteins to cause  
30 misregulated alternative splicing.

## BRIEF SUMMARY OF THE INVENTION

The present disclosure provides methods and compositions for treating diseases associated with aberrant microsatellite expansion employing recombinant adeno-associated virus (rAAV) expressing human muscleblind (MBNL) proteins.

One embodiment of the invention is directed to a method of treating a disease associated with aberrant microsatellite expansion, comprising administering to a mammal in need thereof, a therapeutically effective amount of recombinant adeno-associated virus (rAAV) containing a transgene that encodes a protein selected from the group consisting of MBNL1, MBNL2, MBNL3, and combinations thereof. In one embodiment of the invention, treating comprises ameliorating or eliminating the symptoms of a neuromuscular or neurological condition caused by the aberrant microsatellite expansion. In an additional embodiment of the invention, the neuromuscular condition is myotonic dystrophy.

In other embodiments of the invention, treating comprises reversing the mis-splicing of the Clcn1 skeletal muscle chloride channel, reversing the mis-splicing of the Amyloid beta (A4) precursor protein (APP), reversing the mis-splicing of the NMDA receptor NR1 (GRIN1), reversing the mis-splicing of the Microtubule-associated protein tau (MAPT), or reversing the mis-splicing of TNNT2 (cTNT), respectively.

One embodiment of the invention is directed to a method of treating a disease associated with aberrant microsatellite expansion, comprising administering to a mammal in need thereof, a therapeutically effective amount of recombinant adeno-associated virus (rAAV) containing a transgene that encodes MBNL1.

One embodiment of the invention is directed to a method of treating a disease associated with aberrant microsatellite expansion, comprising administering to a mammal in need thereof, a therapeutically effective amount of recombinant adeno-associated virus (rAAV) containing a transgene that encodes a protein selected from the group consisting of MBNL1, MBNL2, MBNL3, and combinations thereof, wherein the mammal is human. In another embodiment of the invention, the mammal in need of treatment has RNA inclusions in neuronal cells.

One embodiment of the invention is directed to pharmaceutical compositions comprising a recombinant adeno-associated virus (rAAV) containing a transgene that encodes at least one protein selected from the group consisting of MBNL1, MBNL2, MBNL3, and combinations thereof. In another embodiment of the invention, the protein is MBNL1.

The present disclosure also provides a mouse model for myotonic dystrophy, wherein the mouse has a substantial deletion of a muscleblind exon in its genome. Such an animal model for human disease allows the identification and testing of potential therapeutic and preventive agents.

Accordingly, one embodiment of the invention is directed to a mouse model for disease associated with aberrant microsatellite expansion, comprising a mouse having a substantial deletion of *Mbnl1* exon 3 (E3) in the mouse genome, wherein said mouse exhibits symptoms typical of a disease associated with aberrant microsatellite expansion in humans. In another embodiment, the invention is directed to a cell isolated from said mouse. In one embodiment of the invention, the mouse exhibits symptoms such as muscle weakness and ocular cataracts.

In one embodiment, the invention is directed to a mouse model for disease associated with aberrant microsatellite expansion, comprising a mouse having a substantial deletion of *Mbnl1* exon 3 (E3) in the mouse genome, wherein said mouse exhibits symptoms typical of a disease associated with aberrant microsatellite expansion in humans, wherein the microsatellite repeat expansion disease is caused by a microsatellite expansion in a coding region of DNA. In another embodiment of the invention, the microsatellite repeat expansion disease is caused by a microsatellite expansion in a non-coding region of DNA.

In one embodiment, the invention is directed to a mouse model for disease associated with aberrant microsatellite expansion, comprising a mouse having a substantial deletion of *Mbnl1* exon 3 (E3) in the mouse genome, wherein said mouse exhibits symptoms typical of a disease associated with aberrant microsatellite expansion in humans, wherein the mouse exhibits abnormal muscleblind proteins. In other embodiments of the invention, the mouse may have a loss of functional ClC-1 protein, a loss of functional Amyloid beta (A4) precursor protein, a loss of functional NMDA receptor NR1, a loss of functional Microtubule-associated protein tau, a loss of functional TNNT2 protein, or a loss of functional TNNT3 protein, respectively.

One embodiment of the invention is directed to a method of identifying a compound useful in the treatment of disease associated with aberrant microsatellite expansion, comprising administering a test compound to a mouse having a substantial deletion of *Mbnl1* exon 3 (E3) in the mouse genome, wherein said mouse exhibits symptoms typical of a disease associated with aberrant microsatellite expansion in humans, wherein the mouse exhibits abnormal muscleblind proteins, and monitoring said mouse for reduction or inhibition of the symptoms associated with said disease. In an additional embodiment, the mouse may be monitored for effects other than those associated with the disease. In one embodiment of the invention, the disease is myotonic dystrophy.

## BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A shows targeted disruption of *Mbnl1*. The illustration includes C57BL/6J *Mbnl1* exon organization (open boxes, UTRs black boxes, open reading frame) together with the 129S1/*Svlm* insert (black rectangle), the 129 genomic region with *EcoRV* (E) (E site in C57BL/6J) shown by black box with white E, *Xba*I (X), and *Bam* HI (B) sites, the targeting construct with a thymidine kinase marker (TK),

floxed (black triangles, *loxP* sites), neomycin cassette (stippled box with white N), the 129 region (thick black line) and locations of hybridization probes I and II.

FIG. 1B is a genomic analysis of *Mbnl1* mice with the use of probe 1. The 11-kb *EcoRV* fragment is derived from C57BL/6; the mutant is 6.5 kb.

FIG. 1C shows loss of *Mbnl1* E3 expression in *Mbnl1*<sup>ΔE3/ΔE3</sup>

FIG. 1D is an immunoblot analysis (total spleen protein) showing absence of Mbnl1 41-42kD proteins in *Mbnl1*<sup>ΔE3/ΔE3</sup>.

FIG. 2A shows an electromyograph (EMG) of *Mbnl1* wild-type and mutant knockout vastus muscle. The arrow (top panel) indicates normal EMG electrode insertional activity in wild-type muscle, whereas insertion triggers myotonic discharges in *Mbnl1*<sup>ΔE3/ΔE3</sup> muscle (bottom panel).

FIG. 2B shows ClC-1 splicing in DM mouse models. Functional chloride channels are produced when Clcn1 exons 6, 7 and 8 are spliced directly together, whereas isoforms that include cryptic exons 7a or 8a encode truncated non-functional proteins. Clcn1 exons 7 to 8 are illustrated (open boxes) with the primer positions indicated via horizontal arrows. Inclusion of exons 7a and 8a occurs at low levels in wild-type (FVB wt, *Mbnl1*<sup>+/+</sup>) and *Mbnl1*<sup>+/ΔE3</sup> muscle but at increased levels in *Mbnl1*<sup>ΔE3/ΔE3</sup> and *HSA*<sup>LR</sup> muscle.

FIG. 2C and FIG. 2D depict the loss of ClC-1 protein observed in *Mbnl1*<sup>ΔE3/ΔE3</sup> vastus muscle. Representative images of sections from 11-week-old mice show reduced ClC-1 immunostaining in *Mbnl1*<sup>ΔE3/ΔE3</sup> mice (D) relative to wild-type mice (C). Scale bar, 20 μm.

FIG. 2E and FIG. 2F constitute representative images of sections from 11-week-old mice showing equivalent dystrophin (Dys) levels in *Mbnl1*<sup>+/+</sup> (E) and *Mbnl1*<sup>ΔE3/ΔE3</sup> (F) muscle.

FIG. 2G and FIG. 2H depict abnormal muscle histology. Hematoxylin and eosin (H&E)-stained vastus from wild-type (G) and *Mbnl1*<sup>ΔE3/ΔE3</sup> (H) mice, showing split myofibers (black arrowhead) and centralized myonuclei (white arrowhead). Scale bar, 30 μm.

FIG. 2I to FIG. 2L show cataract development. Dilated eyes of 18-week old mice showing a clear wild-type lens (I) but dust-like opacities (white arrowhead) in *Mbnl1*<sup>ΔE3/ΔE3</sup> mice (K). Center bright spot is the lamp reflection. H&E-stained anterior section (J, L) highlight increased fragmentation (black arrowhead) and opacities (white arrowhead) in *Mbnl1*<sup>ΔE3/ΔE3</sup> lens (L) compared to wild-type lens (J).

FIG. 3A and 3B constitute representative images of sections from 11-week-old mice showing similar levels of α-sarcoglycan in (A) wild-type (*Mbnl1*<sup>+/+</sup>) vastus muscle and (B) muscleblind E3 knockout (*Mbnl1*<sup>ΔE3/ΔE3</sup>) vastus muscle.

FIG. 4A shows adult retention of *Tnnt2* exon 5 *Mbnl1*<sup>ΔE3/ΔE3</sup> heart. RT-PCR products with (+) and without (-) exon 5 (black box) are indicated (brackets). Size markers are pBR322 *Msp* I fragments.

FIG. 4B shows *Tnnt3* fetal (F) exon inclusion in adult *Mbnl1*<sup>ΔE3/ΔE3</sup>. The *Tnnt3* protein contains variable N-terminal (alternative splicing of exons 4 to 8 and F) and C-terminal regions (exons 16 and 17)



(23). RT-PCR (11-week-old mice) of *Tnnt3* exons 2 to 11 (left panel) is shown with alternatively spliced exons 4 to 8 and the fetal (F) exon (black boxes). The F exon contains a *Bsr*BI site (arrowhead) resulting in co-migrating smaller fragments in *Mbnl1*<sup>ΔE3/ΔE3</sup> (right panel).

FIG. 4C depicts RT-PCR of *Tnnt3* exons 15 to 18 after *Msc*I digestion.

FIG. 4D shows retention of *Tnnt3* fetal (F) exon in adult DM1 skeletal muscle (left panel). The right panel shows cDNAs containing the F exon (bracket) cleaved with *Bbs*I (arrowhead).

FIG. 5A shows reversal of the skeletal muscle major chloride channel (*Clcn1*) splicing defect following AAV-MBNL1 injection. + lanes represent AAV-mycMBNL1 injection into the Tibialis anterior (TA) muscles of HSA<sup>LR</sup> mice, while – lanes represent injection of PBS into the other leg. Boxes indicate *Clcn1* exons. Shown are the normal (bottom, exons 6, 7, 8 spliced directly together) and aberrant (7a, 8a and intron 6 inclusion) splicing patterns. Mice 190 and 191 are uninjected controls.

FIG. 5B shows an electromyogram depicting the results of the myotonia analysis performed. The scale (Y-axis) runs from 0 to 3, with 3 corresponding to severe myotonia. Zero equals no observed myotonic discharges, 1 equals occasional myotonic discharge, 2 equals abundant myotonic discharges and 3 equals myotonic discharge in nearly every insertion. The X-axis shows the mouse number and whether the TA was injected or uninjected with rAAV1/Myc-hMBNL1.

FIG. 6 shows the results of RT-PCR analysis of exon inclusion. Percent exon inclusion is calculated as ((mRNA+exon)/(mRNA–exon+mRNA+exon)) x 100. Results are derived from at least three independent experiments. Expression of GFP–MBNL1 (~72 kDa), GFP–MBNL2 (~58 kDa), GFP–MBNL3 (~70 kDa) and EGFP (~27 kDa) was detected by Western blot analysis using an anti-GFP monoclonal antibody. All three MBNL proteins promote exon 5 skipping of (A) chicken and (B) human cTNT exon 5 in primary skeletal muscle cultures. (C) All three MBNL proteins promote exon 11 inclusion in a human IR minigene in HEK293 cells. (D) MBNL proteins have minimal effects on splicing of exon EN in a clathrin light-chain B minigene in primary skeletal muscle cultures.

FIG. 7A shows a Western blot confirming depletion of endogenous MBNL1 by independent transfection of two different siRNA constructs using the MBNL1 monoclonal (mAb) 3A4, which recognizes two MBNL1 isoforms generated by alternative splicing (~41 and 42 kDa). GAPDH (~36 kDa) was used as a loading control.

FIG. 7B shows the results of immunofluorescence analysis using mAb 3A4 to confirm depletion of endogenous protein after independent transfection of each MBNL1 siRNA construct. Scale bar, 10 μm. FIG. 7C shows, in bar graph form, the RT-PCR results from at least three transfections.

FIG. 8 shows MBNL1 binds upstream of exon 5 in human cTNT at a site distinct from the CUG-BP1-binding site. (A) Binding of recombinant GST–MBNL1 to uniformly <sup>32</sup>P-labeled RNA was assayed by UV cross-linking. Scanning mutagenesis was performed by replacing 6 nt blocks with AUAAUA and identified two binding sites 18 and 36 nt upstream of the alternative exon. The MBNL1-binding sites (M)

and the CUG-BP1-binding site (C) are located on opposite sides of exon 5. (+) and (–) indicate binding; (•) indicates a putative branch point adenosine. (B) Four nucleotide substitutions significantly reduce binding of recombinant MBNL1 detected by UV cross-linking. Competition of GST–MBNL1 binding to <sup>32</sup>P-labeled RNA G by the indicated picomoles of non-labeled RNAs G or M shown in A). (C, D) MBNL1-binding site mutations reduce responsiveness to MBNL1, MBNL2 and MBNL3 co-expression but not CUG-BP1 in COSM6 cells. Human cTNT minigenes containing the natural sequence (C) or the four nucleotide substitutions (mutation M in A) in the MBNL1-binding site (D) were co-expressed with GFP or the indicated GFP fusion proteins. Exon inclusion was assayed by RT–PCR.

FIG. 9A schematically depicts how the chicken cTNT MSE1–4 RNA contains an alternative exon flanked by four MSEs. Below, FIG. 9A shows the results of the UV-cross-linking assays, wherein GST–MBNL1 bound weakly to MSE1 and strongly to MSE4.

FIG. 9B shows UV-cross-linking assay results for competition of GST–MBNL1 binding to labeled chicken cTNT MSE1–4 RNA by non-labeled MSE RNAs. Picomoles of competitor RNA are indicated. FIG. 9C shows the results of the scanning mutagenesis performed, identifying two MBNL1-binding sites within MSE4.

FIG. 9D shows an alignment of the four MBNL1-binding motifs in human and chicken cTNT, which reveals a common motif.

FIG. 10A shows, in bar graph form, the results of the over-expression and depletion experiments with respect to the wild-type cTNT minigene, co-transfected with the indicated siRNA constructs, a plasmid expressing a DMPK minigene with 960 CUG repeats (Philips *et al.*, 1998) or a GFP–MBNL1 expression plasmid in HeLa cells. FIG. 10B shows the results with respect to the mutant cTNT minigene with point mutations that prevent CUG-BP1 binding and regulation.

FIG. 11A shows, in bar graph form, the results of the over-expression and depletion experiments with respect to the mutant human IR minigene lacking the CUG-BP1-binding site in HEK293 cells. FIG. 11B shows the results with respect to the human IR minigene lacking the CUG-BP1-binding site.

FIG. 12 shows the results of FISH (left panels) and IF (middle panels) analyses of frozen sections of DM1 brain showing nuclear foci of mutant *DMPK* mRNA. FISH, IF, and nuclear stain (DAPI, blue) images are merged in panels on the right. In (A), FISH (without IF) using Texas Red-labeled CAG repeat probe shows an RNA inclusion in frontal cortical neuron. Autofluorescence from lipofuscin occurs at broad spectrum of wavelengths. It appears in every color channel and as yellow-brown perinuclear material in the merged image. RNA inclusions in cerebral cortex are confined to neurons identified by IF for NeuN (B) or MAP2 (C). Small foci are present in cerebellar Purkinje cells (D) or oligodendrocytes of the centrum semiovale (E) identified by IF for calbindin or CNPase, respectively. (F) RNA foci do not colocalize with PML bodies in cortical neurons. Bar, 5 μm, applies to all panels.

FIG. 13 shows RNA foci in dentate gyrus and subcortical neurons in DM1, as visualized by FISH

and IF analysis. FISH (CAG repeat probe, red) merged with IF (anti-NeuN antibody, green) and nuclear stain (DAPI, blue). SN, substantia nigra. Bar, 5  $\mu$ m, applies to all panels.

FIG. 14 (A) shows foci of mutant RNA in neuronal and muscle nuclei, as visualized by FISH and IF analysis. Processing was carried out on the same slide and imaging under the same exposure settings. (B) depicts, in bar graph form, fluorescence area  $\times$  intensity of RNA foci in paired samples of frontal cortex and skeletal muscle from the same patient; n=3 patients, 20 nuclei per sample ( $p < 10^{-10}$ ).

FIG. 15 shows the results of FISH and IF analyses of sections of temporal or frontal cortical neurons showing colocalization of mutant *DMPK* mRNA [(CUG)<sub>n</sub>] with 20S $\alpha$  subunit of proteasome (A), MBNL2 (E), and hnRNP F (F). There is a marked redistribution of MBNL1 into RNA foci in DM1 cortical neurons (G), compared to the distribution in the nucleus (excluding nucleolus) and cytoplasm of normal neurons (H). Mutant *DMPK* mRNA does not colocalize with the PM/Sc1100 (nuclear) component of the exosome (B), CUGBP1 (C), or NF90 (D). RAR $\gamma$  does not colocalize with RNA foci in DM1 cortical neurons (I). The distribution of RAR $\gamma$  in the DM1 (I) and non-neurologic-disease (J) neuronal nucleus is similar. Bar, 5  $\mu$ m, applies to all panels.

FIG. 16 shows the results of FISH analysis combined with IF analysis of sections of DM1 temporal or frontal cortex. FISH (CAG repeat probe, red, left panels) and IF (middle panels, antibody to indicated protein, green) are merged with nuclear stain (DAPI, blue) in right panels. CUG expansion RNA colocalizes with proteasome 11S $\gamma$  subunit (A) and hnRNP H (C) but not with double-stranded RNA binding protein ADAR1 (B), hnRNP M (D), or Sp1 (E). Bar, 5  $\mu$ m, applies to all panels.

FIG. 17 depicts, in graph form, immunofluorescence (area  $\times$  intensity) for MBNL1 in the nucleus, excluding nucleolus and RNA foci, as determined for 20 neurons in sections of temporal cortex from 3 individuals with DM1 and 3 controls without neurologic disease (C).

FIG. 18 shows the regulation of alternative splicing of the NMDA NR1 receptor (*NMDAR1*), amyloid beta precursor protein (*APP*), and microtubule-associated protein tau (MAPT) in DM1. (A) shows splice products obtained by RT-PCR amplification of RNA isolated from non-disease control (n=5) or DM1 (n=7) temporal cortex. Exon utilization for each splice product is shown in diagram. (B) provides quantification of RT-PCR splicing assay (triplicates). ex, exon.

## DETAILED DESCRIPTION OF THE INVENTION

### Muscleblind proteins

Proteins in the muscleblind-like (MBNL) family bind to expanded CUG repeats *in vitro* and colocalize with mutant DM and HSA<sup>LR</sup> transcripts *in vivo*. Human muscleblind genes *MBNL1* (SEQ ID NO: 1), *MBNL2* (SEQ ID NO: 2), and *MBNL3* (SEQ ID NO: 3) are homologous to the *Drosophila* gene muscleblind, which is essential for muscle and eye differentiation. *MBNL1*, the major *MBNL* gene expressed in human skeletal muscle, encodes multiple protein isoforms, including some that bind to

expanded CUG repeats (41 to 42 kD) and others that fail to bind (31 kD isoform), generated by exon 3 skipping.

In fact, MBNL1 was identified in HeLa cells based on its ability to bind double-stranded CUG repeats (Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ, Thornton CA, Swanson MS (2000), *EMBO J* 19: 4439–4448). All three MBNL gene products colocalize with the expanded repeat RNA foci *in vivo* (Fardaei M, Rogers MT, Thorpe HM, Larkin K, Hamshire MG, Harper PS, Brook JD (2002), *Hum Mol Genet* 11: 805–814). Loss of MBNL function due to sequestration on CUG repeat RNA is proposed to play a role in DM pathogenesis (Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ, Thornton CA, Swanson MS (2000), *EMBO J* 19: 4439–4448). Thus, while expression of CUG and CCUG expansion RNAs induces MBNL recruitment into nuclear RNA foci, there is no evidence that this relocation results in muscleblind depletion and functional impairment.

#### **Recombinant adeno-associated vectors**

Recombinant AAV (rAAV) vectors have been used for expressing gene products in animals, see, for example, U.S. Pat. No. 5,193,941 and WO 94/13788. Other patents and publications describe AAV vectors and uses, the uses generally being related to expression of gene products either in vitro (usually tissue cultures) or in vivo (usually in the lungs or oral mucosa, the normal sites of AAV infection, but expression in other tissues, such as the central nervous system and in cardiac tissue has been observed).

AAV vectors have certain advantages over other well-characterized vector systems. First, like adenovirus, AAV infects non-dividing cells. Second, all the AAV viral genes are eliminated in the vector. Since the viral gene expression-induced immune reaction is no longer a concern, AAV vectors are safer than adenovirus vectors. As AAV is an integration virus, integration into the host chromosome will maintain the transgene in the cells. AAV is an extremely stable virus, resistant to many detergents, pH changes and heat (stable at 56 °C for about an hour). AAV can be lyophilized and redissolved without losing significant activity. Finally, AAV causes no known diseases or pathogenic symptoms in humans. Therefore, AAV is a very promising delivery vehicle for gene therapy.

Transduction of rAAV vectors harboring the bacterial  $\beta$ -galactosidase gene by single injection into the quadriceps of mice demonstrated that expression was maintained long-term and the expression did not decrease substantially during that time (Xiao et al., *J. Virol.*, 70:8098-8108 (1996)). Other targets successfully transduced with rAAV vectors include: T-lymphocytes and B-lymphocytes, human erythroleukemia cells, different regions of the rat brain, the striatum of the rat brain in a Parkinson's Disease model with the tyrosine hydroxylase gene, heart of the pig and rat with the LacZ gene, the peripheral auditory system of the guinea pig and bronchial epithelia of the rabbit and monkey.

#### **Embodiments of the invention**

In one embodiment, the invention provides a vector for effective expression of a protein with MBNL1, MBNL2, or MBNL3 (or combinations thereof) function to treat conditions associated with

aberrant microsatellite expansions. In an additional embodiment, the vector of the invention is recombinant adeno-associated virus (rAAV) vectors. In one embodiment of the invention, the rAAV contains a transgene that expresses an MBNL1, MBNL2, or MBNL3 (or combinations thereof) protein. In an additional embodiment, the invention provides a rAAV containing a transgene that expresses  
5 MBNL1 (for example, the 41 kD isoform).

Isolation of the DNA encoding MBNL polypeptides allows one to use methods well-known to the person of ordinary skill in the art to make changes in the codons for specific amino acids such that the codons are "preferred usage" codons for a given species.

In one embodiment, the rAAV of the invention includes a promoter, which directs the initiation of  
10 RNA transcription in the cell of interest. The promoter may be constitutive or regulated. Regulated promoters include inducible promoters and repressible promoters. In an additional embodiment of the invention, the regulation of the promoter is associated with an "operator", to which an inducer or repressor binds. The promoter may be a "ubiquitous" promoter active in essentially all cells of the host organism or may be a promoter with expression more or less specific to the target cells. Known strong  
15 promoters that find common use to obtain high levels of recombinant protein expression include the herpes simplex thymidine kinase promoter, SV40 promoter and LTRs such as that obtained from Moloney leukemia retrovirus. For the gene to be expressed, the coding sequence must be operably linked to a promoter sequence functional in the target cell.

It is not necessary that the AAV-derived sequences correspond exactly with wild-type AAV  
20 prototypes. For example, in one embodiment, the rAAV vectors of the invention may feature modified inverted terminal repeats and other sequences, provided that the rAAV vectors can replicate and be packaged with the assistance of helper virus, and establish a nonpathogenic latent infection in target cells. Typically, because of the packaging limitations of AAV, the polynucleotides encoding MBNL1 domain sequences and the regulatory elements can have a length of up to about 5,500 bases.

Numerous applications of the present invention, e.g., making transgenic constructs, involve the  
25 cloning, synthesis, maintenance, mutagenesis, and other manipulations of nucleic acid sequences that can be performed using routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods of use in this invention include Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd ed. 1989); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and  
30 Current Protocols in Molecular Biology (Ausubel et al., eds., 1994)).

For propagation of the rAAV vectors *in vitro*, susceptible cells are co-transfected with an AAV-derived vector DNA and a suitable AAV-derived helper virus or plasmid harboring the AAV rep gene, AAV cap gene or both and infected by a helper virus, including herpesvirus, adenovirus or a suitable non-AAV helper plasmid using any number of transfection methods, including, inter alia, calcium-phosphate  
35 transfection, lipofection or other techniques known to those skilled in the art. The ratio of helper plasmids

to the quantity of vector plasmid containing the gene of interest range from 1:1-1:10. This procedure produces recombinant AAV vectors; the vector plasmid contains the recombinant AAV genome flanked by the AAV ITRs. The AAV-derived helper virus or helper plasmid may be any virus or plasmid which is capable, on expression of the AAV genes it carries, of providing proteins necessary for the replication and packaging of the rAAV vector in a suitable host cell, for the purpose of producing rAAV vector stock.

In one embodiment, the target cells of the rAAV vectors of the invention are cells capable of expressing polypeptides with MBNL1 activity. In another embodiment of the invention, the cells are normal cells cultured *in vitro*. In further embodiments, the target cells of the rAAV vectors of the invention are human cells, or cells of other mammals, such as nonhuman primates and mammals of the orders Rodenta (mice, rats, rabbit and hamsters), Carnivora (cats and dogs) and Arteriodactyla (cows, pigs, sheep, goats and horses). In one embodiment of the invention, the cells are part of a living mammal at the time the rAAV vectors are delivered to the cell. The mammal may be at any stage of development at the time of delivery, e.g., embryonic, fetal, infantile, juvenile or adult. Additionally, the cells may be healthy or diseased.

In one embodiment, the rAAV vectors of the invention may be administered as viral particles alone, whether as an *in vivo* direct delivery to the vasculature or as an *ex vivo* treatment comprising administering the rAAV vector viral particles *in vitro* to cells from the animal receiving treatment followed by introduction of the transduced cells back into the donor. Alternatively, the rAAV vector virus particles can be used to transduce cells in conjunction with secondary agents known to enhance the efficiency of transduction, see, e.g., WO Ser. No. 95/33824 for a variety of secondary agents. The effective amount of rAAV vectors to be administered will vary from patient to patient. Accordingly, effective amounts are best determined by the physician administering the rAAV vectors, and appropriate dosages can be determined readily by one of ordinary skill in the art.

In one embodiment, the rAAV construct of the invention expresses human MBNL1 (rAAV-MBNL1(rAAV-MBNL1/41)). In an additional embodiment of the invention, injection of the rAAV-MBNL1/41 into the tibialis anterior (TA) muscles of a transgenic model for DM that expresses a human skeletal  $\alpha$ -actin transgene carrying 250 CTG repeats (*HSA<sup>LR</sup>* -- a mouse model which develops myotonia and muscle degeneration similar to muscle abnormalities seen in DM patients) results in a functional reversal of a DM-related phenotype, namely, reversal of mis-splicing of the *Clcn1* skeletal muscle chloride channel, which results in myotonia.

In one embodiment, the invention is directed to methods for treating or preventing various disorders and conditions associated with aberrant microsatellite expansions in a mammal, said method comprising administering to the mammal a therapeutically effective amount of rAAV containing a transgene that encodes a protein selected from the group consisting of MBNL1, MBNL2, MBNL3, and

combinations thereof. In a further embodiment of the invention, the protein is MBNL1. In another embodiment of the invention, the mammal is a human. In another embodiment, the transgene is human. In one embodiment of the invention, the disease associated with aberrant microsatellite expansion is a neurological or neuromuscular disease. In an additional embodiment of the invention, the disease is myotonic dystrophy. In yet another embodiment of the invention, the disease is SCA8.

In additional embodiments, the present invention provides methods for treating or preventing a disease or condition related to any physiological process affected by MBNL1, said method comprising administering to the mammal a therapeutically effective amount of rAAV containing a transgene that expresses the MBNL1 protein.

In one embodiment, the invention is directed to methods for treating or preventing various disorders and conditions associated with aberrant microsatellite expansions in a mammal, said method comprising administering to the mammal a therapeutically effective amount of rAAV containing a transgene that encodes a protein selected from the group consisting of MBNL1, MBNL2, MBNL3, and combinations thereof, wherein treating comprises reversing the mis-splicing of the Clcn1 skeletal muscle chloride channel.

In another embodiment of the invention, treating comprises reversing the mis-splicing of the Amyloid beta (A4) precursor protein (APP). The mis-splicing may correspond to alternative splicing of exon 7. In another embodiment of the invention, treating comprises reversing the mis-splicing of the NMDA receptor NR1 (GRIN1). The mis-splicing may correspond to alternative splicing of exon 5. In yet another embodiment of the invention, treating comprises reversing the mis-splicing of the Microtubule-associated protein tau (MAPT). The mis-splicing may correspond to alternative splicing of exon 2. In yet another embodiment of the invention, treating comprises reversing the mis-splicing of the TNNT2 (cTNT). The mis-splicing may correspond to alternative splicing of exon 5.

In one embodiment, the invention is directed to methods for treating or preventing various disorders and conditions associated with aberrant microsatellite expansions in a mammal, said method comprising administering to the mammal a therapeutically effective amount of rAAV containing a transgene that encodes a protein selected from the group consisting of MBNL1, MBNL2, MBNL3, and combinations thereof, wherein the mammal has RNA inclusions in neuronal cells.

One embodiment of the invention is directed to a pharmaceutical composition comprising rAAV containing a transgene that encodes at least one protein selected from the group consisting of MBNL1, MBNL2, MBNL3, and combinations thereof. In one embodiment of the invention, the protein is MBNL1. Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention (see, e.g., Remington's Pharmaceutical Sciences, 17<sup>th</sup> ed. 1985).

Formulations for both *ex vivo* and *in vivo* administrations include suspensions in liquid or emulsified liquids. The active ingredient (rAAV vector) is often mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients include, for example, water, saline, dextrose, glycerol, ethanol or the like, and combinations thereof. In addition, the composition may contain minor amounts of auxiliary substances, such as, wetting or emulsifying agents, pH buffering agents, stabilizing agents or other reagents that enhance the effectiveness of the pharmaceutical composition.

Formulations suitable for administration include aqueous and non-aqueous solutions, isotonic sterile solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, orally, nasally, topically, intravenously, intraperitoneally, intravesically or intrathecally. The formulations of compounds can be presented in unit-dose or multi-dose scaled containers, such as ampules and vials. Solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. The modulators can also be administered as part a of prepared food or drug.

The dose administered to a patient, in the context of the present invention is often varied to assess the effect of various concentrations of a compound on a transgenic animal. The dose will also be determined by, e.g., the body weight or surface area of the area to be exposed to the compound. In general, the dose equivalent of a modulator is from about 1 ng/kg to 10 mg/kg for a typical subject. Administration can be accomplished via single or divided doses.

Pharmaceutical preparations of the disclosed gene vectors may be administered intravenously, parenterally or intraperitoneally. Solutions of pharmaceutically acceptable salts can be prepared in water suitable mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations will contain a preservative to prevent growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (such as, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the



action of microorganisms can be brought about by various antibacterial and antifungal agents, such as, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.

Solutions of the AAV vector as a free acid (DNA contains acidic phosphate groups) or a pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. A dispersion of AAV particles also can be prepared in glycerol, liquid polyethylene glycols and mixtures thereof and in oils. Under ordinary conditions of storage and use, the preparations contain a preservative to prevent the growth of microorganisms. The sterile aqueous media employed are obtainable by standard techniques well known to those skilled in the art.

Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin. Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

The composition can be formulated in a neutral or salt form. Pharmaceutically-acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.

Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as injectable solutions, drug release capsules and the like.

For parenteral administration in an aqueous solution, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion. Some variation in dosage will necessarily occur depending on the condition of the

subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.

5           The pharmaceutical forms suitable for parenteral administration include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that parenteral administration is possible. The formulation must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and  
10       fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of a dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various  
15       antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.

          Sterile parenteral formulations are prepared by incorporating the AAV vector in the required  
20       amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze drying which  
25       yield a powder of the active ingredient plus any additional desired ingredient from the previously sterile-filtered solution thereof.

          The rAAV containing a transgene that expresses the MBNL1 protein may, for example, be prepared by: culturing a composition comprising cells transiently transfected with an AAV helper plasmid comprising AAV rep and cap nucleic acid sequences encoding AAV rep and cap proteins, an adenoviral  
30       helper plasmid comprising essential adenovirus helper genes selected from the group consisting of E1A, E1B, E2A, E4, E4ORF6, E4ORF6/7, VA, and combinations thereof, and an AAV vector comprising first and second AAV ITRs flanking a DNA sequence encoding MBNL1 polypeptide, said sequence being operably linked to a promoter DNA sequence, in the absence of adenovirus particles and under conditions suitable for production of recombinant AAV, and purifying rAAV therefrom.

35           In one embodiment, the invention is directed to a transgenic animal having a substantial deletion

of one or more MBNL1 exon(s). The transgenic animals of the invention can be any mammal other than humans. In one embodiment, the mammal is a rodent. In another embodiment of the invention, the rodent is a mouse. An additional embodiment is directed to a cell isolated from the transgenic animal of the invention.

5 In a further embodiment, the transgenic animal of the invention has a substantial deletion of Mbnl1 exon 3. In one embodiment, Mbnl1 exon 3 in the transgenic animal of the invention is deleted in its entirety.

In one embodiment of the invention, the transgenic mouse having a substantial deletion of Mbnl1 exon 3 constitutes an animal model for microsatellite expansion disease in mammals. In another  
10 embodiment of the invention, the mammal is a primate. In yet another embodiment of the invention, the primate is a human.

In one embodiment of the invention, the microsatellite expansion disease is caused by a microsatellite expansion in a coding region of DNA. In another embodiment of the invention, the microsatellite expansion disease is caused by a microsatellite expansion in a non-coding region of DNA.

15 In one embodiment of the invention, the disease associated with aberrant expansion of microsatellites is myotonic dystrophy. Accordingly, in one embodiment of the invention, the mouse Mbnl1 gene knockout model exhibits myotonia and ocular cataracts.

In one embodiment, the invention is directed to a mouse model for disease associated with aberrant microsatellite expansion, comprising a mouse having a substantial deletion of *Mbnl1* exon 3 (E3)  
20 in the mouse genome, wherein said mouse exhibits symptoms typical of a disease associated with aberrant microsatellite expansion in humans, wherein said mouse has loss of functional CIC-1 protein. In another embodiment of the invention, mouse has loss of functional Amyloid beta (A4) precursor protein. In another embodiment of the invention, the mouse has loss of functional NMDA receptor NR1. In yet another embodiment of the invention, the mouse has loss of functional Microtubule-associated protein  
25 tau. In another embodiment of the invention, the mouse has loss of functional TNNT2 protein. In another embodiment of the invention, the mouse has loss of functional TNNT3 protein.

One embodiment is directed to methods for preparing the transgenic animals of the invention. The transgenic animal of the invention may, for example, be prepared by transfecting a plurality of mouse embryonic stem cells with a nucleic acid comprising an MBNL1 gene with a substantial deletion of exon  
30 3, selecting for transgenic embryonic stem cells having incorporated said nucleic acid into their genome, introducing at least one of said transgenic embryonic stem cells into an embryo to produce a chimeric mouse comprising at least one of said transgenic embryonic stem cells, breeding said chimeric mouse with a wild-type mouse to obtain F1 progeny heterozygous for the MBNL1 gene with a deletion of exon 3, and breeding a male mouse of said F1 progeny with a female mouse of said F1 progeny to obtain F2  
35 progeny homozygous for MBNL1 gene with a deletion of exon 3, wherein the said mouse exhibits a

phenotype indicative disease associated with aberrant microsatellite expansion, for example, myotonic dystrophy.

Additional embodiments are directed to methods for using the transgenic animals of the invention as animal models to study MBNL1 function *in vivo*, and for evaluating side effects of MBNL1-inhibiting compounds. For example, if a compound known to inhibit MBNL1 is administered to an MBNL1 knockout mouse, any detected effects of the compound on the mouse can be concluded to be MBNL1-independent.

In further embodiments, the transgenic mammals of the invention, and cells thereof, can be used as animal models to identify compounds useful in the treatment of diseases associated with aberrant microsatellite expansions (such as, in one embodiment, myotonic dystrophy) and to assess the functional effect of a test compound on cells or animals afflicted with such disease. Such compounds can be any small chemical compound, including polypeptides, polynucleotides, amino acids, nucleotides, carbohydrates, lipids, or any other organic or inorganic molecule. Alternatively, the compounds can be genetically altered versions of the MBNL1 gene.

In one embodiment of the invention, assessing the effects of a compound on cells or animals, e.g., the transgenic animals of the invention having a substantial deletion of MBNL1 exon 3, involves providing a combinatorial chemical or peptide library containing a large number of potential therapeutic compounds (potential modulator or binding compounds). Such "combinatorial chemical libraries" are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical "building blocks" such as reagents. Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Pat. No. 5,010,175, Furka (1991) *Int. J. Pept. Prot. Res.*, 37:487-493 and Houghton, et al. (1991) *Nature*, 354:84-88).

To assess the effect of a compound on an animal, or to treat or prevent a condition associated with aberrant microsatellite expansion, for example, myotonic dystrophy, in an animal, administration of the compound can be achieved by any of the routes normally used for introducing a compound into ultimate contact with the tissue to be treated. The compounds are administered in any suitable manner, optionally with pharmaceutically acceptable carriers. Suitable methods of administering such compounds are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.

Although MBNL1 is referred to in the individual descriptions of the embodiments of the invention, MBNL2 and MBNL3 may likewise be contemplated for each embodiment.

#### **Definitions**

A "transgene" refers to genetic material that is introduced, or is capable of being introduced, into cells of a host animal. Typically, once a "transgene" is introduced into the cells of the host animal, it is maintained, either transiently or permanently, by, e.g., insertion into the host genome. In preferred embodiments of the present invention, a transgene is inserted into the host genome by homologous recombination, thereby replacing the endogenous gene with the transgene. Often, a transgene contains a coding sequence, operably linked to a promoter, that encodes a protein, e.g., a marker protein that allows the detection of the transgene in the cell. "Transgenic" refers to any cell or organism that comprises a transgene.

A "host" animal or mammal refers to any animal that is used to practice the herein-described methods, i.e. animals into which a transgene is introduced to disrupt an endogenous MBNL1 gene. For use in the present invention, such animals include any non-human mammals including, but not limited to, mice, rats, rabbits, and hamsters.

"Nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. The term nucleic acid is used interchangeably with gene, cDNA and nucleotide.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants,

interspecies homologs, and alleles of the invention.

A "label" or a "detectable moiety" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include <sup>32</sup>P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide.

The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., 60% identity, optionally 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity over a specified region), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Such

sequences are then said to be "substantially identical."

The term "immunoassay" is an assay that uses an antibody to specifically bind an antigen. The immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the antigen.

5 The phrase "specifically (or selectively) binds" to an antibody or "specifically (or selectively) immunoreactive with," when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein at least two times the background and do not substantially bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies raised to an MBNL1 polypeptide from specific species such as rat, mouse, or human can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with the MBNL1 protein and not with other proteins, except for polymorphic variants and alleles of the MBNL1 protein.

10 The term "transduction" refers to the introduction of foreign DNA into cells of an organism (*in vivo*).

The term "transfection" refers to the introduction of foreign DNA into cells in culture (*in vitro*). Genetic modification of eukaryotic cells by introduction of foreign DNA using chemical means. In transient transfection, expression occurs from unintegrated foreign DNA and can be detected for a few days after transfection.

20 The term "titer" refers to the number of virus particles produced per ml. The assay system to determine the number of virus particles produced varies considerably depending on the virus in question. High titers are generally essential for successful gene therapy since they allow introduction of the therapeutic gene carried by the virus into the maximum number of cells.

25 The terms "treating" and "treatment" as used herein include any treatment of a condition or disease in a subject, and include inhibiting the disease or condition, (i.e. arresting its development), relieving the disease or condition (i.e. causing some degree of regression of the condition or delaying progression in the disease), or relieving (to some degree) the conditions caused by the disease (i.e. symptoms of the disease).

30 The term "vector" refers to a vehicle, usually a biological entity, such as a virus, used for the delivery of genes into an organism. A reagent that facilitates the introduction of foreign genes into cells.

The phrase "packaging cells" refers to cells that have been transfected with plasmids containing the cap and rep genes from AAV.

35 As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.

The use of such media and agents for pharmaceutically-active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

5           The phrase "pharmaceutically-acceptable" refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human. The preparation of an aqueous composition that contains a protein as an active ingredient is well understood in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The  
10       preparation can also be emulsified.

A "substantial" deletion of exon 3 signifies a deletion extensive enough to lend to the phenotype indicative of a disease associated with aberrant microsatellite expansion.

Use of the terms "an", "a" and "the" and similar terms used in claiming or describing the invention are intended to be construed as including both the singular and plural, unless clearly otherwise indicated  
15       or contraindicated. The terms "including", "having" and "containing" are to be construed as open-ended in the same manner as the terms "comprising" or "comprises" are commonly accepted as including but not limiting to the explicitly set forth subject matter. The term "comprising" and the like are construed to encompass the phrases "consisting of" and "consisting essentially of".

The methods and processes described herein may be performed in any suitable order unless  
20       otherwise indicated or clearly rendered inoperable by a modification in order.

Limited and narrow interpretation of descriptive language intended to better illustrate the invention is not to be construed as limiting in any way nor to limit the scope of the invention contemplated by the inventors.

The invention, now described generally and in some detail, will be understood more readily by  
25       reference to the following examples, which are provided by way of reference and are in no manner intended to limit the scope of what the inventors regard as their invention.

## EXAMPLES

Example 1. Characterization of *Mbn11*<sup>ΔE3/ΔE3</sup> mice.

30       Targeted disruption of *Mbn11*: to test whether or not sequestration of MBNL proteins contributes to DM pathogenesis, mice with a targeted deletion of *Mbn11* exon 3 (E3) (Fig. 1A) were generated. The *pMbn11*<sup>ΔE3neo</sup> targeting plasmid was constructed using pTKflNeo (gift of E. Scott, University of Florida), which contains the Herpes simplex virus - thymidine kinase (HSV-TK) negative selection marker and a loxP-flanked phosphoglycerate kinase-neomycin (PGK-Neo) positive selection cassette. A 2.5 kb *Xba*I  
35       fragment (5' arm of homology) corresponding to the upstream region bordering *Mbn11* exon 3, was



inserted 5' of PGK-Neo. For the 3' arm of homology, a 6 kb *Mbnl1* *BamHI* fragment was subcloned into pBluescript II KS<sup>+</sup> (Stratagene, La Jolla, CA), excised with *XhoI/NotI*, and cloned into the *XhoI/NotI* sites of pTKflNeo 3' of PGK-Neo.

The pMbnl1<sup>ΔE3neo</sup> plasmid was linearized with *NotI* and electroporated into CJ.7 ES cells (P.J. Swiatek, T. Gridley, *Genes & Dev.* **7**, 2071 (1993)). ES cells were cultured and selected as described in T. Yang *et al.*, *Nat. Genet.* **19**, 25 (1998). Clones resistant to G418 and FIAU were isolated and screened for homologous recombination by utilizing a forward primer (5'-TGGGATGGAATTGTGGTGTGTTGTTGCTCATG-3') (SEQ ID NO: 4) outside the 5' homologous region and a reverse primer (5'-TCCATTTGTCACGTCCTGCACCGACGC-3') (SEQ ID NO: 5) in PGKNeo. Amplification (25 cycles) consisted of 98°C for 20 s followed by 68°C for 4 min. Targeted ES cell clones yielded a 2.9 kb PCR product. This targeting strategy was predicted to approximate the situation in DM by eliminating synthesis of CUG-binding isoforms (Miller, *et al.*, 2000).

Genomic DNA analysis of Mbnl1 mice: genomic blot analysis demonstrated successful deletion of Mbnl1<sup>ΔE3/ΔE3</sup> mice (Fig. 1B). Five ES cell clones (35, 56, 92, 111, 120) that were positive for homologous recombination were confirmed by genomic DNA blot analysis. Based on restriction map analysis of genomic fragments flanking E3, ES genomic DNA digested with *EcoRV* produces a 16 kb band when a 300 nt *Mbnl1* *BamHI/EcoRV* fragment outside the 3' arm of homology is used as a hybridization probe (probe II of Fig. 1A). In the targeted allele, a new *EcoRV* site (from pBluescript II KS<sup>+</sup>) is introduced, generating a novel 6.7 kb *EcoRV* fragment. All five clones that were positive by PCR were also positive by genomic DNA blot analysis. When the 5' arm of homology (2.5 kb *XbaI* fragment) was used as probe, two bands at 16 kb (wild type) and 7.5 kb (mutant) were detected. To check for additional insertion events in these five clones, PGK-Neo fragment was used as probe on genomic DNA digested with *EcoRV*. A single band at 7.5 kb confirmed the absence of any additional insertion events.

One ES clone (ES.35) was expanded and transiently transfected with Cre recombinase to excise PGK-Neo. To detect PGK-Neo loss, forward (5'-CTACGATGGCTGGCTGCAATATGCCTCACTGTAAG-3') (SEQ ID NO: 6) and reverse (5'-GGGTTGAATCTCGTTAGGGACACTGGGTGTCTGTAA-3') (SEQ ID NO: 7) primers were used for a PCR screen. PCR was performed for 30 cycles, each cycle consisting of 96°C for 30 sec, 60°C for 30 sec and 72°C for 2 min. Clones positive for PGK-Neo deletion yielded a 1 kb band and cassette excision was confirmed by genomic DNA blot analysis. Utilization of a PCR-generated subfragment of the 5' arm of homology as a hybridization probe yielded *EcoRV* bands at 16 kb and 6.5 kb. The loss of PGK-Neo results in decrease in the size of the mutant allele digested with *EcoRV* from 7.5 to 6.5 kb. The Neo excised allele was designated *Mbnl1*<sup>ΔE3</sup>.

Two *Mbnl1*<sup>+/ΔE3</sup> ES clones (1B3, 2C1) were transferred to 3.5 dpc C57BL/6J blastocysts which were then carried to term by B6D2F1/J recipients. One chimeric male was obtained from each clone.

Contribution of CJ.7 (129S1/SvImJ) ES cells to the germline was determined by mating the chimeric males with C57BL/6J females. Agouti pups in litters sired by the 1B3 chimeric male indicated germline transmission.

To detect heterozygotes in the F1 population derived from 1 B3, a combination of one forward primer (5'-CTACGATGGCTGGCTGCAATATGCCTCACTGTAAG-3') (SEQ ID NO: 8) and two reverse primers [for the mutant allele (5'GGGTTGAATCTCGTTAGGGACACTGGGTGTCTGTAA-3' (SEQ ID NO: 9)); [for the wild-type allele (5'-TGGCAGACCCTTTGACACCG-3') (SEQ ID NO: 10)] were used for PCR. Amplification was performed for 30 cycles, each cycle consisting of 96°C for 30 sec, 60°C for 30 sec and 72°C for 2 min. Heterozygotes were then mated to obtain *Mbnl1*<sup>ΔE3/ΔE3</sup> mice.

Loss of Mbnl1 E3 expression in Mbnl1<sup>ΔE3/ΔE3</sup>: loss of E3 expression was confirmed by reverse transcription polymerase chain reaction (RT-PCR); primers in exons 3 and 6 were used to amplify a cDNA product from either *Mbnl1*<sup>+/+</sup> or *Mbnl1*<sup>+/ΔE3</sup> mice that was absent in *Mbnl1*<sup>ΔE3/ΔE3</sup> mice (Fig. 1C). To confirm loss of exon 3, an RT-PCR strategy was used with the forward primer positioned in exon 3 (5'-TAGTGTCACACCAATTCGGGACACAAA-3') (SEQ ID NO: 11) and an exon 6 reverse primer (5'CCCTTGATGTAATCCATGCAGACAGTGA-3') (SEQ ID NO: 12). Continued transcription of *Mbnl1* in *Mbnl1*<sup>ΔE3/ΔE3</sup> lines was examined using exon 10 forward (5'-TGCACGGTGCTACGCCAGCC-3') (SEQ ID NO: 13) and exon 12 reverse (5'GTGACGACAGCTCTACATCTGGGTAACA-3') (SEQ ID NO: 14) primers, as well as exon 13 forward (5'-CCTGCTGCACACTGTTGCCTACAC-3') (SEQ ID NO: 15) and reverse (5'TGTCAGTTCCCTCCCTCACCATGT-3') (SEQ ID NO: 16) primers. For amplification, 27 cycles were performed each consisting of 45 sec at 95°C, 45 sec at 55°C and 45 sec at 72°C, followed by a final 10 min extension at 72°C. As expected, *Mbnl1* expression was not fully eliminated in *Mbnl1*<sup>ΔE3/ΔE3</sup> mice; RT-PCR products were apparent with primers in constitutively spliced exons 10 and 12, or within exon 13.

Immunoblot analysis (total spleen protein): for immunological detection of Mbnl1, tissues were placed in homogenization buffer (50 mM Tris-Cl [pH=8.0], 150 mM NaCl, 2 mM phenylmethylsulfonyl fluoride, 6 μg/ml aprotinin, 1 μg/ml leupeptin) and disrupted using a Polytron homogenizer and brief sonication (3 X 5 sec using a microtip sonicator). Following addition of IGEPAL CA-630 (Sigma) to 1%, homogenates were incubated on ice for 15 min, centrifuged at 16,000 X g for 10 min. Proteins (30 μg per lane) were detected following SDS-PAGE and immunoblotting using anti-Mbnl1 mAb 3A4 (J. W. Miller *et al.*, *EMBO J.* **19**, 4439 (2000), A. Mankodi *et al.*, *Ann. Neurol.*, in press). Total spleen was analyzed (Fig. 1D), because this tissue contains relatively high levels of both Mbnl1 and Cugbp1.

To confirm elimination of the Mbnl1 41- to 42-kD proteins in *Mbnl1*<sup>ΔE3/ΔE3</sup> mice, monoclonal antibody 3A4 was used, which recognizes Mbnl1 proteins containing exon 5[MS1]. The 41- to 42-kD isoforms in *Mbnl1*<sup>+/+</sup> and *Mbnl1*<sup>+/ΔE3</sup> mice were missing in *Mbnl1*<sup>ΔE3/ΔE3</sup> (Fig. 1D). Previous studies suggested that elevated levels of another RNA-binding protein, CUGBP1, are responsible for DM-

associated RNA splicing changes. However, *Mbnl1*<sup>ΔE3/ΔE3</sup> mice did not show increased CUGBP1 expression (Fig. 1D).

#### Example 2. Myotonia and cataracts

**Electromyography:** electromyography was performed under general anesthesia (intraperitoneal ketamine, 100 mg/kg; xylazine, 10 mg/kg; and acepromazine, 3 mg/kg) using 30 gauge concentric needle electrodes to examine three hindlimb (tibialis anterior, gastrocnemius, vastus), two forelimb (flexor compartment of distal forelimb, triceps), and thoracolumbar paraspinal muscles. At least 10 needle insertions were performed in each muscle and myotonic discharges were graded on a 4 point scale: 0, no myotonia; 1, occasional myotonic discharge in <50% of needle insertions; 2, myotonic discharge with > 50% of insertions; and 3, myotonic discharge with nearly all insertions. The mean score across all *Mbnl1*<sup>ΔE3/ΔE3</sup> limb muscles was 2.9 in mice age 7 to 11 weeks (n=10). Myotonic discharges were not observed in any muscle in heterozygous *Mbnl1*<sup>+ΔE3</sup> mice (n=9) or wild-type littermates (n=9).

*Mbnl1*<sup>ΔE3/ΔE3</sup> mice display overt myotonia beginning around 6 weeks of age. Delayed muscle relaxation was most noticeable after a period of rest and showed improvement during activity. A similar "warm up" phenomenon is characteristic of myotonia in human DM. Electromyographic recordings confirmed myotonic discharges in all *Mbnl1*<sup>ΔE3/ΔE3</sup> mice tested (n = 10) (Fig. 2A).

**ClC-1 splicing in DM mouse models:** because myotonia in DM1 and DM2 muscle is associated with aberrant ClC-1 splicing, RT-PCR assays were used to investigate the effect of loss of *Mbnl1* E3 on ClC-1 (encoded by *Clcn1*) expression (Fig. 2B). Total cellular RNA was extracted from either quadriceps or heart muscle of *Mbnl1*<sup>+/+</sup>, *Mbnl1*<sup>+ΔE3</sup> and *Mbnl1*<sup>ΔE3/ΔE3</sup> mice by homogenizing the tissues in TRI-REAGENT (Sigma, St. Louis, MO.) according to manufacturer's protocol. First strand cDNA was generated by reverse transcription (RT) using 5 μg of total RNA and SuperScript II RNase H<sup>-</sup> RT (Invitrogen, Carlsbad, CA) following the manufacturer's protocol. For subsequent PCR reactions, 20% of the RT reaction was used as template. Each PCR reaction was spiked with 10 μCi of (α<sup>32</sup>P)-dCTP (PerkinElmer Life Sciences, Boston, MA). PCR products were resolved on 5-8% non-denaturing polyacrylamide gels followed by autoradiography using Biomax MS film (Eastman Kodak, Rochester, NY).

For ClC-1 mRNA analysis, the forward primer used corresponded to exon 5 (5'-GGAATACCTCACACTCAAGGCC-3') (SEQ ID NO: 17) and the reverse primer to exon 8 (5'-CACGGAACACAAAGGCACTGAATGT-3') (SEQ ID NO: 18). PCR was performed for 27 cycles each consisting of 45 sec at 95°C, 45 sec at 55°C and 45 sec at 72°C, followed by a final 10min extension at 72°C. Full-length ClC-1 cDNA clones were generated from muscle RNA by RT-PCR as previously described (A. Mankodi *et al.*, *Mol. Cell* 10, 35 (2002)). Sequence analysis of 10 clones from *Mbnl1*<sup>ΔE3/ΔE3</sup> mice revealed 6 clones with inclusion of exon 7a and 2 clones with retention of intron 2. All splice junctions were normal in 10 clones derived from wild-type littermates.

Remarkably, *Mbnl1*<sup>ΔE3/ΔE3</sup> mice showed abnormal inclusion of *Clcn1* cryptic exons 7a and 8a in a pattern similar to that seen in *HSA*<sup>LR</sup> mice. Also, some full-length ClC-1 cDNA clones from *Mbnl1*<sup>ΔE3/ΔE3</sup> mice showed abnormal inclusion of intron 2, as has been observed in DM and *HSA*<sup>LR</sup> muscle. Notably, these abnormal splice isoforms have premature termination codons and do not encode functional chloride channels. By contrast, splicing of the *Scn4a* sodium channel, the only other ion channel previously associated with myotonia was normal in *Mbnl1*<sup>ΔE3/ΔE3</sup> muscle. These results suggested that changes in splice site selection result in the loss of functional ClC-1 from myofiber membranes.

ClC-1, Dys2, and α-sarcoglycan immunostaining: frozen sections of vastus (6 μm) were immunostained using polyclonal antibodies directed against the C-terminus of ClC-1 (Alpha Diagnostic, San Antonio) or monoclonal antibodies to dystrophin (Dys2) or α-sarcoglycan (NovoCastra, Newcastle upon Tyne) as described in A. Mankodi *et al.*, *Mol. Cell* **10**, 35 (2002).

Immunofluorescence analysis confirmed a major reduction of ClC-1 protein in *Mbnl1*<sup>ΔE3/ΔE3</sup> muscle relative to the muscle of wild-type sibs (Fig. 2, C and D), whereas the membrane-associated proteins dystrophin (Fig. 2, E and F) and α-sarcoglycan (Fig. 3) were unaffected. Because abnormalities of ClC-1 splicing in *Mbnl1*<sup>ΔE3/ΔE3</sup> muscle are more pronounced than in *HSA*<sup>LR</sup> muscle, and considering that *HSA*<sup>LR</sup> mice have a >80% reduction of chloride conductance, it is likely that myotonia in *Mbnl1*<sup>ΔE3/ΔE3</sup> mice is due to improper ClC-1 pre-mRNA splicing.

Analysis of muscle histology: frozen sections (10 μm) of vastus and gastrocnemius muscle were prepared for routine histologic (hematoxylin and eosin, modified Gomori trichrome, periodic acid-Schiff) and histochemical (cytochrome oxidase, acid phosphatase, nicotinamide adenine dinucleotide-tetrazolium reductase, myosin ATPase, succinate dehydrogenase) stains (V. Dubowitz, *Muscle Biopsy, A Practical Approach* (Bailliere Tindall, London, ed. 2, 1996)).

Histological analysis of *Mbnl1*<sup>ΔE3/ΔE3</sup> mice up to 11 weeks of age did not show major degeneration of muscle fibers. Pathological features in *Mbnl1*<sup>+ΔE3/ΔE3</sup> muscle included an increase in nuclei with an abnormal (central) position and splitting of myofibers (Fig. 2, G and H). Histologic abnormalities were not observed in *Mbnl1*<sup>+/+</sup> or *Mbnl1*<sup>+ΔE3</sup> muscle.

Cataract development: besides muscle abnormalities, distinctive ocular cataracts that progress from subcapsular "dust-like" opacities to mature cataracts are a prominent DM-associated feature. Similar cataracts were observed in all *Mbnl1*<sup>ΔE3/ΔE3</sup> eyes examined (*n* = 24; 3 to 8 months old) but not in wild-type siblings (Fig. 2, I to L).

For ocular lens evaluation, mice were sedated using intra-peritoneal injection of 100 mg/kg ketamine (Ketaset, Fort Dodge, IA) and 10 mg/kg xylazine (Xylaject, Phoenix, St Joseph, MO) and anterior chambers and lenses were examined using a slit lamp (Haag Streit, Mason, OH). *In vivo* images were obtained using a Nikon 990 digital camera attached to the slit-lamp. Immediately after euthanasia, globes were enucleated, fixed in paraformaldehyde and embedded in paraffin blocks before being

processed overnight in a Shandon Excelsior tissue processor (Thermo Electron, Waltham, MA). Sections (4  $\mu$ m) were cut using an HM-315 microtome (Richard-Allan, Kalamazoo, MI), dried and H&E stained. Sections were photographed using a Canon EOS D60 digital camera attached to an Olympus Vanox microscope.

### Example 3. Pre-mRNA splicing

Abnormal regulation of alternative splicing – Tnnt2: abnormal regulation of alternative splicing has been observed in DM1 muscle for cardiac troponin T (TNNT2), insulin receptor (INSR), and CIC-1. Tnnt2 was analyzed using exon 2 forward (5'GCCGAGGAGGTGGTGGAGGAGTA-3') (SEQ ID NO: 19) exon 6 reverse (5'GTCTCAGCCTCACCTCAGGCTCA-3') (SEQ ID NO: 20) and 27 PCR cycles (45 sec at 96°C, 45 sec at 58°C and 45 sec at 72°C, followed by a final 10-min extension at 72°C). Analysis of INSR is uninformative because human patterns of INSR alternative splicing are not conserved in mice. However, *Mbn1l* <sup>$\Delta E3/\Delta E3$</sup>  adult heart shows abnormal retention of the *Tnnt2* "fetal" exon 5 (Fig. 4A), as was observed for DM1.

Abnormal regulation of alternative splicing – Tnnt3: to determine whether alternative splicing of other genes is disrupted in *Mbn1l* <sup>$\Delta E3/\Delta E3$</sup> , fast skeletal muscle troponin T (Tnnt3) was assessed. For mouse Tnnt3, the forward primer overlaps exons 2 and 3 (5'TCTGACGAGGAACTGAACAAG-3') (SEQ ID NO: 21) while the reverse primer (5'TGTCAATGAGGGCTTGGAG-3') (SEQ ID NO: 22) corresponds to exon 11. For human TNNT3, exon 2 forward (5'-TTCACCATGTCTGACGAGGAAG-3') (SEQ ID NO: 23) and exon 10 reverse (5'CTTCTGGGATCTTAGGAGCAGTG-3') (SEQ ID NO: 24) primers were used. For mouse Tnnt3 and human TNNT3, 25 PCR cycles were performed each consisting of 45 sec at 95°C, 45 sec at 50°C and 30 sec at 72°C, followed by a final 10-min extension at 72°C. The same amplification protocol was used to amplify the mouse Tnnt3 carboxyl terminal region using an exon 15 forward primer (5'- CCTTGTTACCAACTGGAGACTGAC-3') (SEQ ID NO: 25) and an exon 18 reverse primer (5'- TGATGGTCTCTGCTGCAGTG -3') (SEQ ID NO: 26).

Primers in *Tnnt3* exons 2 and 11 produced a single major RT-PCR product in adult *Mbn1l*<sup>+/+</sup> and *Mbn1l*<sup>+/ $\Delta E3$</sup>  mice that was undetectable in *Mbn1l* <sup>$\Delta E3/\Delta E3$</sup>  mice (Fig. 4B). Instead, a cluster of larger cDNAs, all containing a "fetal" (F) exon, was prominent. In contrast, mutually exclusive splicing of *Tnnt3* exons 16 and 17 was unaffected in *Mbn1l* <sup>$\Delta E3/\Delta E3$</sup>  mice; this finding shows that altered *Mbn1l* expression has specific effects on splice site selection even within the same pre-mRNA (Fig. 4C). Similar alterations of TNNT3 splicing in adult DM1 muscle (Fig. 4D) were found.

Abnormal regulation of alternative splicing – Scn4a: missense mutations in the Scn4a muscle-specific sodium channel are also associated with myotonia. The Scn4a pre-mRNA has two rare AT/AC splice sites but is not known to undergo alternative splicing. To screen for abnormalities of Scn4a splicing that might contribute to myotonia, RT-PCR analysis of muscle RNA was carried out. Partial cDNAs covering the entire Scn4a coding region (GenBank accession# AJ278787) were generated by PCR using

the following primers: set 1 exon 1 (GACCTGGAAGCTGGCAAGAAC) (SEQ ID NO: 27) to exon 6  
 (TCCCTTCGTCATTGATGTAGGC) (SEQ ID NO: 28); set 2 exon 6  
 (CCATGAATGACACCAACACCAC) (SEQ ID NO: 29) to exon 12  
 (CTGAGGGTGACGATGAAGCTG) (SEQ ID NO: 30); set 3 exon 12  
 (TCTTCACGGGCATCTTCACTG) (SEQ ID NO: 31) to exon 17  
 (CGCCGCTGTTCAATGTAGATG) (SEQ ID NO: 32); and set 4 exon 16  
 (TGCCTCTATGTGGACATCTCCC) (SEQ ID NO: 33) to exon 24  
 (CGACTCTTTCTTGACGTAGGCG) (SEQ ID NO: 34). RT-PCR products from primer sets 1, 2, 3,  
 and 4 was analyzed on 1 % agarose gels before and after restriction digest with *ApaI*, *NcoI*, *BspEI* and  
*BsrGI* -*HindIII*, respectively. Results showed no difference in the length of *Scn4a* cDNA fragments in  
*Mbnl1*<sup>+/+</sup>, *Mbnl1*<sup>+/ $\Delta$ E3</sup>, *Mbnl1* <sup>$\Delta$ E3/ $\Delta$ E3</sup> or *HSA*<sup>LR</sup> mice (data not shown).

Loss of specific *Mbnl1* isoforms that associate with expanded (CUG)<sub>n</sub> and (CCUG)<sub>n</sub> RNAs is  
 sufficient to cause myotonia, cataracts, and RNA splicing defects that are similar to those seen in DM.  
 Although muscleblind-like proteins may influence gene expression at multiple levels, these proteins may  
 play a direct role in splice site selection. Recent co-transfection analysis in HEK293 cells using a *Tnnt3*  
 mini-gene indicated that the *Mbnl1* 41 kDa protein regulates alternative splice site choice by binding to a  
 discrete RNA element upstream of the fetal (F) exon. Thus, MBNL proteins bind to distinct RNA  
 sequence elements and influence exon use during splicing.

Young *Mbnl1* <sup>$\Delta$ E3/ $\Delta$ E3</sup> mice do not develop the severe neonatal muscle weakness associated with  
 congenital DM1, and it is not yet known whether cardiac conduction problems develop in this model.  
 Thus, some aspects of the DM phenotype may not result from loss of *MBNL1* function alone. Additional  
 muscleblind proteins (MBNL2 and MBNL3) are also recruited to nuclear RNA foci. It is contemplated  
 that their sequestration may be required to fully replicate the multisystemic DM phenotype.

#### Example 4. AAV-MBNL1 injection and *Clcn1* splicing

*HSA*<sup>LR</sup> mice were anesthetized using isoflurane, and the left tibialis anterior (TA) muscle was  
 injected with 13.4  $\mu$ L PBS containing  $1 \times 10^{11}$  rAAV1Myc-hMBNL1, or the right leg was injected with  
 PBS ("uninjected"). Four weeks post-injection, the mice were anesthetized using 2.5% avertin, and the  
 left and right TAs were collected for total RNA preparation and assayed for recovery of the normal *Clcn1*  
 pre-mRNA splicing pattern (Fig. 5A)

Reverse transcription was carried out using 5  $\mu$ g of total RNA and 300 ng of random hexamers in  
 a final volume of 20  $\mu$ L. After, RNase H treatment for 15 minutes at 37°C, 4  $\mu$ L of cDNA was used for  
 PCR. The final volume of the PCR reaction was 50  $\mu$ L, which contained 30 pmoles of forward primer (5'-  
 TGAAGGAATACCTCACACTCAAGGCC-3') (SEQ ID NO: 40) in exon 5 of *Clcn1* and 30 pmoles of  
 reverse primer (5'-CACGGAACACAAAGGCACTGAATGT-3') (SEQ ID NO: 41) in exon 8 of *Clcn1*.  
 In addition, the reaction was spiked with 10  $\mu$ Ci of dCTP-[ $\alpha$ <sup>32</sup>P]. 27 cycles were carried out at annealing

and extension temperatures of 55°C and 72°C, respectively. Thirty percent of the total PCR products were resolved on a 5% acrylamide gel followed by exposure of the gel to an autoradiography film.

Mice number 188 and 189 were injected on the same day and processed together. Mouse number 190 and 191 were littermates that were neither injected with virus nor with PBS (included as uninjected controls). The results show that the levels of the abnormal splicing products were decreased, while the level of the normal splicing product was increased, following rAAV1Myc-hMBNL1 injection.

The mice were also tested for myotonia by electromyography (EMG). Four weeks post-injection, EMG was performed on the injected and uninjected (the latter corresponding, for this example, to those mice not injected with virus, but, rather, with PBS alone) TA of six *HSA<sup>LR</sup>* mice. The Y-axis shows the observed severity of myotonia following insertion of the electrode. Five out of six mice showed virtual elimination of myotonia in the injected TA muscles (injected with virus), while, in the uninjected TA of the same animal, robust myotonia (grade level=3) was observed. The results show that injection of the *HSA<sup>LR</sup>* mice with rAAV1Myc-hMBNL1 (41 kDa isoform expressed) into the tibialis anterior results in reduced myotonia in as little as four weeks' time.

#### Example 5. Effect of MBNL proteins on alternative splicing

To determine whether MBNL proteins can alter the splicing patterns of pre-mRNAs known to be abnormally regulated in DM1 striated muscle, GFP fusion proteins of all three MBNL proteins were transiently expressed with human and chicken cTNT minigenes in primary chicken skeletal muscle cultures. GFP fusions with MBNL1, 2 and 3 were provided by Dr JD Brook (Fardaei M, Rogers MT, Thorpe HM, Larkin K, Hamshire MG, Harper PS, Brook JD (2002), *Hum Mol Genet* 11: 805–814). The cTNT, IR and clathrin light chain B minigenes were previously described (Kosaki A, Nelson J, Webster NJ (1998), *J Biol Chem* 273: 10331–10337; Philips AV, Timchenko LT, Cooper TA (1998), *Science* 280: 737–741; Stamm S, Casper D, Hanson V, Helfman DM (1999), *Brain Res Mol Brain Res* 64: 108–118; Ladd AN, Charlet-B N, Cooper TA (2001), *Mol Cell Biol* 21: 1285–1296). The MBNL mutant human cTNT minigene was generated by inverse PCR.

Transient transfection and RT-PCR analysis: HEK293 cells were plated at 500 000 cells per well in a six-well plate in DMEM supplemented with 10% FBS and Gibco penicillin–streptomycin. At 24 h after plating, the cells were transfected with 1 µg of minigene and 2 µg of protein expression plasmid using Fugene6 (Roche, Indianapolis, IN), according to the manufacturer's directions. Protein and RNA were harvested 36–48 h after transfection.

Human and chicken cTNT and human IR minigenes were expressed with or without each of the three GFP–MBNL fusion proteins or with GFP alone. Duplicate transfections were used for extraction of RNA and protein. Inclusion of cTNT exon 5 or IR exon 11 was assayed by RT-PCR.

Chicken primary muscle cultures were prepared, maintained and transfected as previously described, using 0.5 µg minigene reporter and 1 µg expression plasmid (Xu R, Teng J, Cooper TA (1993),

*Mol Cell Biol* 13: 3660–3674). COSM6 cells were plated at 150 000 cells per well in a six-well plate in DMEM supplemented with 10% FBS, Gibco penicillin–streptomycin and L-glutamine. At 24 h after plating, the cells were transfected with 500 ng of minigene and 1 µg of protein expression plasmid using Fugene6 (Roche, Indianapolis, IN) according to the manufacturer's directions. Protein and RNA were harvested 36–48 h after transfection. RNA isolation and RT–PCR analysis for the cTNT, IR, and clathrin light-chain B minigenes were performed as described previously (Philips AV, Timchenko LT, Cooper TA (1998), *Science* 280: 737–741; Stamm S, Casper D, Hanson V, Helfman DM (1999), *Brain Res Mol Brain Res* 64: 108–118; Savkur RS, Philips AV, Cooper TA (2001), *Nat Genet* 29: 40–47).

Western blot analysis to investigate alternative splicing related to MBNL: cells were harvested in protein loading buffer (62.5 mM Tris–HCl (pH 6.8), 2% SDS, 10% glycerol and 5% 2-β-mercaptoethanol) and the protein concentration was quantitated with the Non-Interfering Protein Assay (Genotech, St Louis, MO). Total protein lysates from HEK293 (20 µg) and primary chicken skeletal (30 µg) cultures were loaded on a 12.5% acrylamide gel and transferred to Immobilon-P membranes (Millipore, Bedford, MA). GFP was detected using JL-8 monoclonal antibody (BD Biosciences, Palo Alto, CA) at a dilution of 1:2000. The secondary antibody was a goat anti-mouse HRP conjugate (Jackson Immunoresearch, West Grove, PA) at a dilution of 1:5000.

To detect endogenous MBNL1, HeLa (50 µg) protein lysates were loaded on a 12.5% acrylamide gel. Blots were probed with the monoclonal 3A4 (16 mg/ml) at a dilution of 1:500. The secondary antibody was a sheep anti-mouse HRP conjugate (Amersham Biosciences, Piscataway, NJ) at a dilution of 1:5000. For GAPDH in HeLa cells, 15 µg of total protein lysates was run on a 12.5% acrylamide gel, transferred to membranes and detected using the 6G5 monoclonal (Biogenesis, Kingston, NH) at a dilution of 1:100 000. The secondary antibody was a goat anti-mouse HRP conjugate (Jackson Immunoresearch, West Grove, PA) at a dilution of 1:5000.

GFP–MBNL1, 2 and 3 strongly repressed inclusion of both human and chicken cTNT exon 5 in primary chicken skeletal muscle cultures, while expression of GFP to levels comparable to, or greater than, GFP–MBNL fusion proteins had no effect on splicing (Figure 6A and 6B). Of note, GFP–MBNL1 was found to have a novel MBNL1 isoform lacking exons 7, 9 and 10 and containing a frameshift in exon 12. In addition, there were no differences in the splicing activity of GFP fusion proteins compared to Xpress epitope-tagged MBNL proteins (data not shown). Therefore, MBNL proteins are directly antagonistic to endogenous CELF activity, which activates cTNT exon inclusion in muscle (Charlet-B N, Logan P, Singh G, Cooper TA (2002a), *Mol Cell* 9: 649–658).

Another pre-mRNA target that is misregulated in DM striated muscle is the IR (Savkur RS, Philips AV, Cooper TA (2001), *Nat Genet* 29: 40–47; Savkur RS, Philips AV, Cooper TA, Dalton JC, Moseley ML, Ranum LP, Day JW (2004), *Am J Hum Genet* 74: 1309–1313). To test whether the MBNL family can also regulate human IR, the three MBNL family members were co-expressed with a



human IR minigene. In contrast to the inhibitory effect of MBNL on cTNT splicing, coexpression of MBNL family members with an IR minigene strongly induces exon inclusion, whereas GFP alone had no effect (Figure 6C).

To determine whether the MBNL family has a general effect on alternative splicing, all three MBNL proteins were co-expressed with a clathrin light-chain minigene containing the neuron-specific exon EN. The EN alternative exon in this minigene strongly responds to over-expression of the SR family of proteins and htra2- $\beta$ 1, but not CELF proteins (Stamm S, Casper D, Hanson V, Helfman DM (1999), *Brain Res Mol Brain Res* **64**: 108–118; Singh G, Charlet BN, Han J, Cooper TA (2004), *Nucleic Acids Res* **32**: 1232–1241; data not shown). Over-expression of GFP–MBNL1, 2 and 3 with the clathrin light-chain minigene had no effect on alternative splicing of exon EN (Figure 6D). MBNL expression also did not affect splicing of an artificial alternative exon flanked by splice sites from human  $\beta$ -globin intron 1 (data not shown). These results demonstrate that MBNL proteins do not have a general effect on alternative splicing, but, rather regulate specific pre-mRNA targets. In summary, MBNL1, 2 and 3 regulate splicing of cTNT and IR alternative exons.

#### Example 6. siRNA-mediated depletion of MBNL1 and splicing of cTNT and IR

To determine whether depletion of endogenous MBNL1 protein could also affect the splicing patterns of known DM pre-mRNA targets in human cells, siRNA constructs were designed to target MBNL1, but not MBNL2 and MBNL3. To confirm the specificity of the effects, two siRNA constructs were designed to target different regions of the MBNL1 mRNA.

SiRNA construct design and transfection: two custom siRNA duplexes were designed for RNAi against human MBNL1 using the Dharmacon siDESIGN program ([www.dharmacon.com](http://www.dharmacon.com)) (<http://www.dharmacon.com/>) and were synthesized by Dharmacon. The sequences are as follows: THH31 mRNA target (AA-N19 format 5'  $\rightarrow$  3') AACAGACAGACUUGAGGUAUG (SEQ ID NO: 35), THH2 mRNA target (AA-N19 format 5'  $\rightarrow$  3') AACACGGAAUGUAAAUUUGCA (SEQ ID NO: 36), GFP siRNA duplex (Dharmacon, Lafayette, CO cat. no. D-001300-01-20). 300 000 HeLa cells were plated in 2 ml of antibiotic-free growth media (DMEM supplemented with 10% FBS) per well in a six-well plate. HeLa cells were chosen because they express MBNL1 (Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ, Thornton CA, Swanson MS (2000), *EMBO J* **19**: 4439–4448) and are amenable to siRNA-mediated depletion (Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001), *Nature* **411**: 494–498).

At 12 h after plating, the media was exchanged with 800  $\mu$ l serum-free media (DMEM) per well. siRNA duplex (2.66  $\mu$ g) was transfected using Oligofectamine (Invitrogen, Carlsbad, CA). 1 ml of 3 x serum-containing media (DMEM supplemented with 30% FBS) was added after 4 h. After 12 h, the 3 x serum-containing media was replaced with antibiotic-free growth media and the cells were transfected with 1  $\mu$ g of minigene and 2.66  $\mu$ g of siRNA duplex using Lipofectamine 2000 (Invitrogen, Carlsbad,

CA). The media was exchanged with antibiotic-free growth media 6 h later. RNA and protein were harvested 48 h after transfection of the minigene.

Independent transient transfection of each siRNA construct resulted in a knockdown of endogenous MBNL1 protein to less than 10–20%, based on comparisons to serial dilutions of the untransfected or mock-transfected lysates (Figure 7A; data not shown).

Immunofluorescence analysis of MBNL1 depletion: HeLa cells were grown on coverslips in six-well plates and transfected with 2.66 µg siRNA using Oligofectamine. The coverslips were washed with cold PBS (pH 7.4) and fixed in 4% paraformaldehyde/PBS for 15 min. After three washes with PBS, the cells were dehydrated with 70% ethanol overnight at 4°C. The coverslips were then rehydrated with PBS for 10 min and incubated with 3% BSA/PBS for 15 min at room temperature. The cells were washed once with PBS and incubated with the primary antibody 3A4 (10 mg/ml) at a dilution of 1:1000 in 3% BSA/PBS at room temperature for 1 h. The cells were then washed three times with PBS and incubated with the secondary antibody, Alexa Fluor-labeled goat anti-mouse IgG (2 mg/ml, Molecular Probes, Eugene, OR), at a dilution of 1:100 in 3% BSA/PBS at room temperature for 1 h. The cells were then washed with PBS three times, counterstained with DAPI (Molecular Probes, Eugene, OR) and mounted for visualization by fluorescence microscopy.

Analysis of MBNL1 depletion by immunofluorescence demonstrated predominantly nuclear expression that was greatly reduced in the majority of cells by each siRNA construct (Figure 7B). In addition, the siRNA constructs silenced effectively the expression of GFP–MBNL1, but not GFP–MBNL2, GFP–MBNL3 or GFP from transiently transfected plasmids, and neither MBNL1 siRNA affected the levels of endogenous MBNL2 protein (data not shown). These results indicate that the siRNAs preferentially silence MBNL1.

MBNL1 depletion and cTNT and IR minigene splicing: to determine whether depletion of endogenous MBNL1 affected alternative splicing of cTNT, IR and clathrin light chain, the minigenes were transfected with each siRNA construct. Depletion of MBNL1 promoted exon inclusion in cTNT, exon skipping in IR and only minimal splicing changes in the clathrin light-chain minigene (Figure 7C). siRNA-mediated depletion of MBNL1 with two independent constructs reproduces the DM splicing patterns for cTNT and IR minigenes. GFP siRNA had no effect on splicing of any of the tested minigenes. MBNL1 siRNA had minimal effects on splicing of a rat clathrin light-chain minigene.

These splicing effects were not caused by general activation of the mammalian RNAi machinery because siRNA targeting GFP or luciferase and nonspecific pools of siRNA had minimal effects on splicing of the three minigenes (Figure 7C; plus data not shown). Furthermore, the alteration in cTNT splicing caused by MBNL1 depletion in HeLa cells can be reversed by expression of GFP–MBNL2 or GFP–MBNL3, but not GFP (data not shown), demonstrating that adding back MBNL isoforms not targeted by MBNL1 siRNA rescues the splicing effects of MBNL1 deficiency.

The data indicate that endogenous MBNL1 regulates the splicing of human cTNT and IR minigenes. Interestingly, siRNA-mediated depletion of MBNL1 reproduces the splicing pattern observed in DM1 for cTNT (exon inclusion) and IR (exon skipping), and is opposite to the pattern observed when MBNL1 is over-expressed. The over-expression and depletion data indicate that endogenous MBNL1 regulates the alternative splicing of cTNT and IR minigenes, and suggest that MBNL1 regulates these pre-mRNAs via specific *cis*-regulatory elements. The effects of MBNL on the cTNT and IR alternative exons are the opposite of the splicing patterns induced by CELF proteins, implying an antagonistic relationship between these protein families.

Example 7. Binding of MBNL1 to introns adjacent to the human and chicken cTNT alternative exons

UV cross-linking analysis of MBNL1 binding to human cTNT: to determine whether the splicing effects of MBNL1 on pre-mRNA targets were direct or indirect, a UV-cross-linking assay was performed using purified recombinant GST-MBNL1 and uniformly labeled *in vitro*-transcribed segments from the human cTNT gene. Uniformly <sup>32</sup>P-labeled RNAs were transcribed *in vitro* using [ $\alpha$ -<sup>32</sup>P]GTP and [ $\alpha$ -<sup>32</sup>P]UTP (Perkin-Elmer, Wellesley, MA) from PCR products or cloned regions of the human or chicken introns 4 and 5, as represented in Figures 8 and 9.

UV-cross-linking assays were performed using radiolabeled transcripts standardized for picomoles of G and U. UV-cross-linking assays included 1  $\mu$ g of purified GST-MBNL1 in the presence of 1  $\mu$ g BSA, 1  $\mu$ g tRNA, 0.3  $\mu$ g heparin, 0.3 mM magnesium acetate, in 2 mM magnesium acetate, 2 mM ATP, 16 mM HEPES (pH 7.9), 65 mM potassium glutamate, 0.16 mM EDTA, 0.4 mM DTT and 16% glycerol. Binding was for 10 min at 30°C. Recombinant GST-MBNL1 protein was produced as described (Miller JW, Urbinati CR, Teng-Umnuaay P, Stenberg MG, Byrne BJ, Thornton CA, Swanson MS (2000), *EMBO J* 19: 4439–4448). Competitions were performed as described previously (Singh G, Charlet BN, Han J, Cooper TA (2004), *Nucleic Acids Res* 32: 1232–1241). The indicated amounts of non-labeled competitor RNAs were added to the binding reaction 10 min prior to addition of labeled substrate RNA.

The human cTNT minigene contains a 732 nucleotide (nt) cTNT genomic fragment that is necessary and sufficient to respond to MBNL1 over-expression and depletion (Figures 6 and 7C). To identify MBNL1-binding sites within this cTNT pre-mRNA region, uniformly <sup>32</sup>P-labeled, *in vitro*-transcribed RNAs covering the entire region were used for UV-cross-linking binding assays. As shown in Figure 8A, the binding of GST-MBNL1 on human cTNT was mapped to a 41 nt region within the 3' splice site of exon 5 (compare RNAs C, D, E and F) located between a near-consensus branch point sequence and the 3' cleavage site of the upstream intron.

Scanning mutagenesis identification of binding sites: scanning mutagenesis identified two MBNL1-binding sites located 18 and 36 nt upstream from exon 5 (Figure 8A). The absence of binding to long intronic segments (RNAs F and C) and RNAs containing nucleotide substitutions (RNAs H, J and M;

see below) demonstrate binding specificity. This analysis indicates that, for cTNT, the MBNL1-binding site is distinct from the CUG-BP1-binding site, which is located downstream from the alternative exon (Philips AV, Timchenko LT, Cooper TA (1998), *Science* **280**: 737–741).

UV cross-linking analysis of binding of MBNL1 with nucleotide substitutions: nucleotide

5 substitutions that disrupt both MBNL1-binding sites were introduced into the human cTNT minigene to test whether MBNL1 binding was required to affect responsiveness to MBNL1 expression *in vivo*. As the MBNL-binding site is located within the 3' splice site of intron 4, only four nucleotide substitutions were introduced to reduce the effects of MBNL-binding site mutations on basal splicing efficiency (RNA M, Figure 8A). These substitutions prevented binding of recombinant MBNL1 to an RNA that is otherwise  
10 identical to RNA G containing the wild-type sequence (Figure 8B). In addition, non-labeled RNA M was much less efficient than RNA G in competing binding of MBNL1 to labeled RNA G (Figure 8B).

When introduced into the human cTNT minigene, the MBNL1-binding site mutation significantly reduced (MBNL1 and MBNL3) or eliminated (MBNL2) responsiveness to MBNL proteins (Figures 8C and 8D), demonstrating that loss of MBNL1 binding *in vitro* directly correlates with decreased  
15 responsiveness to MBNL1 *in vivo*. These results demonstrate that regulation by MBNL protein is mediated via binding the pre-mRNA, and suggest that all three MBNL proteins regulate human cTNT splicing by binding to the same site. In contrast, the MBNL1-binding site mutations had little effect on responsiveness to CUG-BP1 (Figures 8C and 8D). GFP alone had minimal effects on splicing. Thus, MBNL proteins regulate splicing by binding to the human cTNT pre-mRNA, and regulation by CUG-BP1  
20 does not require the MBNL1-binding site.

UV cross-linking analysis of MBNL1 binding to chicken cTNT: UV-cross-linking analysis was performed to identify MBNL1-binding site(s) associated with the chicken cTNT alternative exon 5. The genomic segment of chicken cTNT that responds to MBNL expression contains 99 and 142 nt of upstream and downstream introns flanking the alternative exon, respectively. Within the intronic  
25 segments are four muscle-specific splicing enhancers (MSEs, Figure 9A) previously shown to be required for enhanced exon inclusion in embryonic striated muscle (Ryan KJ, Cooper TA (1996), *Mol Cell Biol* **16**: 4014–4023; Cooper TA (1998), *Mol Cell Biol* **18**: 4519–4525) and required for regulation by all the six CELF family members (Ladd AN, Charlet-B N, Cooper TA (2001), *Mol Cell Biol* **21**: 1285–1296; Ladd AN, Nguyen NH, Malhotra K, Cooper TA (2004), *J Biol Chem* **279**: 17756–17764). RNAs containing  
30 MSEs 1–4 or individual MSEs were transcribed *in vitro* as uniformly <sup>32</sup>P-labeled RNAs and used for UV cross-linking. GST–MBNL1 bound strongly to MSE4 and slightly to MSE1 (Figure 9A).

In competition studies, non-labeled MSE1 RNA poorly competed in the binding of GST–MBNL1 to RNA containing MSE1–4, while MSE4 effectively competed in binding (Figure 9B), consistent with the UV-cross-linking results. The absence of competition by MSE2 or MSE3 demonstrates the sequence  
35 specificity of MBNL1 binding (Figure 9B). To define the MBNL1-binding site(s) within MSE4, scanning

mutagenesis was performed. Two regions required for MBNL1 binding were identified at 94 and 120 nt downstream from the exon (Figure 9C). Alignment of the four MBNL1-binding sites in chicken and human cTNT revealed a common motif of YGCU(U/G)Y (Figure 9D). Taken together, these data indicate that MBNL1 directly binds to introns adjacent to the human and chicken cTNT alternative exons.

Of note, proteins from all three MBNL genes contain two pairs of Cys3His zinc-finger-related motifs with identical spacing between cysteine and histidine residues in fingers 1 and 3 (CX7CX6CX3H) and fingers 2 and 4 (CX7CX4CX3H) (Miller JW, Urbinati CR, Teng-Umuay P, Stenberg MG, Byrne BJ, Thornton CA, Swanson MS (2000), *EMBO J* 19: 4439–4448; Fardaei M, Rogers MT, Thorpe HM, Larkin K, Hamshire MG, Harper PS, Brook JD (2002), *Hum Mol Genet* 11: 805–814; Squillace RM, Chenault DM, Wang EH (2002), *Dev Biol* 250: 218–230). The Cys3His-type zinc-finger is an evolutionarily conserved motif found in a number of proteins that perform diverse RNA-processing functions, and mutation of this motif results in a loss of RNA binding and disrupts protein function (Bai C, Tolia PP (1996), *Mol Cell Biol* 16: 6661–6667; Bai C, Tolia PP (1998), *Nucleic Acids Res* 26: 1597–1604; Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, Blackshear PJ (1999), *Mol Cell Biol* 19: 4311–4323; Stoecklin G, Colombi M, Raineri I, Leuenberger S, Mallaun M, Schmidlin M, Gross B, Lu M, Kitamura T, Moroni C (2002), *EMBO J* 21: 4709–4718).

MBNL1 also binds to specific sequences within single-stranded RNA, consistent with the results from other Cys3His zinc-finger proteins (Cheng Y, Kato N, Wang W, Li J, Chen X (2003), *Dev Cell* 4: 53–66; Michel SL, Guerrierio AL, Berg JM (2003), *Biochemistry* 42: 4626–4630). The above-delineated results demonstrate that MBNL1 binds to cis-elements in chicken cTNT intron 5 required for muscle-specific splicing.

Example 8. CELF protein cis-regulatory elements in cTNT and IR and regulation by MBNL1

The CUG-BP1-binding site located downstream from exon 5 in the human cTNT minigene is required for regulation by all six CELF proteins (Philips AV, Timchenko LT, Cooper TA (1998), *Science* 280: 737–741; T Ho, unpublished data), and is distinct from the MBNL-binding site mapped in Figure 8. The results shown previously demonstrate that CUG-BP1 regulates minigenes in which MBNL1-binding site mutations have greatly reduced or eliminated MBNL responsiveness (Figure 8D).

Analysis of the importance of the CUG-BP1 binding site to minigene regulation by MBNL1: to determine whether MBNL1 can regulate minigenes lacking the CUG-BP1-binding site, GFP-MBNL1 or MBNL1 siRNA was cotransfected with a human cTNT minigene containing mutated CUG-BP1-binding sites. Plasmids expressing DMPK exons 11–15 containing 960 interrupted CUG repeats in exon 15 were cloned using techniques as previously described (Philips AV, Timchenko LT, Cooper TA (1998), *Science* 280: 737–741). The over-expression and depletion results demonstrate that cTNT minigenes containing the mutant and wild-type CUG-BP1-binding sites are equally responsive to MBNL1 (Figures 10A and 10B). GFP-MBNL2 and 3 also showed similar regulation of wild-type and mutant human cTNT

minigenes (data not shown). These results indicate that the regulation of human cTNT by MBNL1 is independent of CELF regulation.

Similarly, for the IR minigene, regulation by CUG-BP1 requires a CUG-BP1-binding site in a 110 nt region located upstream of IR exon 11 (Savkur RS, Philips AV, Cooper TA (2001), *Nat Genet* 29: 40–47). A mutant IR minigene lacking the CUG-BP1-binding site was co-expressed with GFP-MBNL1, 2 and 3 in HEK293 cells (Figure 11A) or MBNL1 siRNA constructs in HeLa cells (Figure 11B) to determine whether regulation by MBNL proteins requires the CUG-BP1-binding site. The mutant IR minigenes displayed regulation by MBNL proteins, which was comparable to the wild-type IR minigenes (compare Figures 11A and 6C and 11B and 7C). These results indicate that regulation of human cTNT and IR by MBNL proteins does not require the CUG-BP1-binding site. In other words, the deletion of the human IR CUG-BP1-binding site does not affect regulation by MBNL1. All three of the MBNL proteins promoted exon 11 inclusion of the mutant human IR minigene lacking the CUG-BP1-binding site in HEK293 cells (FIG. 11A). Furthermore, RNAi depletion of MBNL1 in HeLa cells using the indicated siRNA constructs promoted exon 11 skipping in the human IR minigene lacking the CUG-BP1-binding site (FIG. 11B).

Mutant cTNT and IR minigenes lacking the CUG-BP1-binding site respond as strongly as non-mutated minigenes to MBNL1 depletion by RNAi (Figures 10B and 11B). However, neither of these minigenes respond to the *trans*-dominant effects of co-expressed CUG repeat RNA as do the non-mutated minigenes (Philips AV, Timchenko LT, Cooper TA (1998), *Science* 280: 737–741; Savkur RS, Philips AV, Cooper TA (2001), *Nat Genet* 29: 40–47; 960CTG, Figure 9). The RNAi results demonstrate that the mutated cTNT and IR minigenes are ‘competent’ to respond to MBNL1 depletion, and, yet, they do not respond to co-expression of CUG repeat RNA. Therefore, while it has been demonstrated that MBNL proteins are alternative splicing regulators of cTNT and IR alternative exons, these results indicate that MBNL depletion by CUG repeat RNA is not sufficient to account for the *trans*-dominant effect of CUG repeat RNA on splicing.

As shown previously, and in Figure 10B, here, the cTNT and IR minigenes made insensitive to CELF regulation by mutations in the CUG-BP1-binding site no longer respond to expanded CUG repeat RNA, suggesting that the *trans*-dominant effect is mediated at least in part via an intact CUG-BP1-binding site (Figure 10B; Philips AV, Timchenko LT, Cooper TA (1998), *Science* 280: 737–741; Savkur RS, Philips AV, Cooper TA (2001), *Nat Genet* 29: 40–47). The present results show that the mutated cTNT and IR minigenes are competent to respond to MBNL depletion by RNAi as strongly as the non-mutated minigenes, yet they do not respond to CUG repeat RNA. If expanded CUG repeats affected cTNT and IR splicing simply by sequestering and depleting MBNL, then the co-expression of CUG repeats should have affected splicing of the mutated as well as non-mutated minigenes. It is, thus, indicated that the repeats have a *trans*-dominant effect on splicing by a mechanism more complex than MBNL depletion

alone.

Example 9. Fluorescence in situ hybridization (FISH) and immunofluorescence (IF) analysis of DM1 brain

Origin and preparation of tissue samples: to study the expression and distribution of expanded poly(CUG)RNA in relation to putative RNA binding proteins in the brain, autopsy materials were obtained from ten DM1 patients (mean age 56 years, range 44-78 years, 7 men and 3 women) and 13 controls (6 with no neurologic disease, 2 with Alzheimer disease, 4 with Huntington disease, and one with refractory epilepsy). The mean post-mortem interval for DM1 patients was 6 hours (range 2 to 14 hours). At the time of autopsy, coronal sections of brain were prepared and placed on aluminum slabs cooled on dry ice. In addition, selected regions were dissected and flash frozen in liquid nitrogen. All samples were stored at -70°C.

Nine of the DM1 patients had signs of classical DM1 before age 30 and died of complications related to the disease (respiratory failure in 7, sudden cardiac death in 2). The other DM1 patient had minimal symptoms of DM1 and died at age 78 yrs of unrelated disease. Genetic confirmation was performed as previously described by PCR or Southern blot on DNA isolated from postmortem brain tissue (Thornton, C.A., Johnson, K., and Moxley, R.T. (1994), *Ann. Neurol.*, 35, 104-107). Southern blots of cortical DNA samples showed a broad range of expanded alleles ranging in size from 5 to 12 kb (not shown). The individual with the minimal DM phenotype had a CTG repeat expansion length of 77 repeats in DNA isolated from peripheral blood, brain, and other tissues.

Fluorescence in situ hybridization (FISH) analysis of brain sections: FISH was performed as described (Mankodi, A., Urbinati, C.R., Yuan, Q.P., Moxley, R.T., Sansone, V., Krym, M., Henderson, D., Schalling, M., Swanson, M.S., and Thornton, C.A. (2001), *Hum. Mol. Genet.*, 10, 2165-2170) with slight modifications. Frozen sections (12 µm) were fixed in 3% paraformaldehyde PBS for 30 min, permeabilized in 2% acetone PBS (pre-chilled at -20°C) for 5 min, and then prehybridized in 30% formamide and 2 X SSC at room temperature for 10 min. Next, sections were hybridized with probe (1 ng/µl) for 2 h at 37°C in buffer (30% formamide, 2 X SSC, 0.02 % BSA, 66 µg/ml yeast rRNA, 2 mM vanadyl complex) and then washed for 30 min in 30% formamide/2XSSC at 42°C followed by 1X SSC for 30 min at room temperature. Probes were HPLCpurified 2-O-methyl RNA 20-mers (IDT, Coralville, IA) composed of CAG-, CUG- or GUC- repeats, and labeled with Texas Red at the 5' end. Images were obtained on an Olympus AX70 epifluorescence microscope at 1,000-fold magnification. To compare the relative fluorescence intensities for RNA foci, sections were processed on the same slide, imaged under the same illumination and exposure settings, and then analyzed using MCID v6.0 software (Imaging Research Inc., St. Catharines, Ontario).

Fluorescence *in situ* hybridization (FISH) of brain sections with CAG repeat probes revealed nuclear RNA foci in every individual with DM1 (n=10, Fig. 12A) but not in controls with (n=7) or

without (n=6) neurologic disease. RNA foci were not observed with CUG (sense) or GUC repeat probes. The hybridization of CAG probes to nuclear foci in DM1 did not require denaturation of genomic DNA. These results indicate that CAG repeat probes recognize CUG expansion RNA rather than a cross-reactive RNA or DNA.

5 Nuclear RNA foci ranged in diameter from 0.2 to 2  $\mu$ m. Resolution of these small structures required direct fluorescence detection methods. However, the autofluorescent material in brain (lipofuscin) was a complicating factor. The RNA foci were clearly distinguished from lipofuscin when the epifluorescence from three color channels was merged in a single image. As shown in Fig. 12A, the nuclear foci appeared in a single channel determined by the probe label (Texas red). Lipofuscin, which excites and emits  
10 at a broad spectrum of wavelengths, generated signal in all channels and appeared as a different color (typically yellow-brown) in the merged image. These observations formed the basis for distinguishing RNA foci in subsequent experiments. RNA foci were red, sharply demarcated structures in the nucleus. Lipofuscin was yellow-brown perinuclear material with indistinct margins.

15 Immunofluorescence (IF) combined with FISH: to determine which cells express mutant *DMPK* and form RNA inclusions, different brain regions were surveyed using FISH in combination with antibodies that mark specific cell types. In cerebral cortex, the nuclear foci were distributed throughout all cortical layers and were confined to neurons, as determined by immunofluorescence (IF) for neuronal markers NeuN (Fig. 12B) or MAP2 (Fig. 12C).

Target Antigen	Final Dilution
Muscleblind	mAb (3B10): 1:1500
(MBNL1)	pAb (EXP 42): 1:1500
Muscleblind	mAb (2D9): 1:10,000
(MBNL2)	
CUGBP1	mAb (3B1): 1:500
CELF4	pAb (#440): 1:500
ETR3	pAb (#163): 1:1500
PKR	pAb (pT451): 1:500
	pAb (M515): 1:500
	pAb (D20): 1:500
	mAb (B10): 1:500
RNA helicase A	pAb 1:500
ADAR1	mAb: 1:500
HRBP	pAb (#1683): 1:500



<b>Target Antigen</b>	<b>Final Dilution</b>
NF90 (DRBP76)	pAb (p90 AB4): 1:500
Staufen	pAb 1:500 (AB 5819)
Proteasome	
19S S10a	pAb: 1:500
11S $\alpha$	pAb: 1:1000
11S $\gamma$	pAb: 1:1000
20S $\beta$ 3 (HC10)	mAb: 1:500
20S $\alpha$	pAb: 1:1000
Ubiquitin	pAb: 1:1000
p80 coilin	pAb: (R288): 1:500
C23 nucleolin	mAb: 1:500
PML	pAb: 1:500
PTB	pAb: 1:500
PM-Scl 75	pAb: 1:500
hnRNP H	
C-terminal	pAb: 1:100
N-terminal	pAb: 1:500
hnRNP F	pAb: 1:1000
hnRNP H	pAb: 1:1000
hnRNP F	pAb: 1:1000
hnRNPI/PTB	pAb: 1:1000
KSRP	pAb: 1:1000
4F4 (hnRNP C)	mAb: 1:500
1D8 (hnRNP M)	mAb: 1:500
CNPase	mAb: 1:1000
MAP2	mAb: 1:500
NeuN	mAb: 1:500
Sp1 (sc-59)	pAb: 1:500
RAR $\gamma$ (sc-550)	pAb: 1:500
Staufen (AB5819)	pAb: 1:500
SUMO-1	mAb

Following the 1 X SSC post-hybridization wash of the FISH procedure, sections were incubated in

primary antibodies (Table 1, above) overnight at 4°C, washed five times with PBS for 2 min, and then incubated in secondary antibody (Alexa 488-labeled goat anti-rabbit polyclonal or Alexa 488-labeled goat anti-mouse polyclonal, Molecular Probes) and 33 nM diamidino-2-phenylindole (DAPI) for 30 min at room temperature. The antibody sources were as follows: CELF4 and ETR3 (T. Cooper, TX), PKR and C23 nucleolin and PML (Biosource Intl, CA), RNA helicase A (C. Lee, NJ), ADAR1 (D. Cho, PA), NF90 (G. Sen, OH), Staufen and NeuN (Chemicon, CA), proteasome (Affiniti, UK), Ubiquitin (DAKO, DK), p80 coilin (KL Chan, CA), PTB (E. Wagner, NC), PM-Scl 75 and hn RNP H and F (J. Wilusz, NJ and D. Black, CA), CNPase and MAP2 (Sigma, MO), Sp1 and RAR $\gamma$  (Santa Cruz Biotechnology, CA), and SUMO-1 (Zymed Laboratories, Inc., CA). Sections were washed five times in PBS prior to mounting.

To estimate relative MBNL1 concentration in nucleoplasm in DM1 nuclei vs. controls, sections of temporal cortex were processed on the same slide and imaged under the same exposure settings. Merged images for Texas red (to visualize RNA foci), Alexa 488 (for MBNL1) and DAPI (for nuclear DNA) were obtained. Regions of interest were manually defined as nuclear area excluding nucleolus, RNA foci, and overlapping lipofuscin. MBNL1 fluorescence intensity (mean optical density in monochrome mode in arbitrary units) in the region of interest was determined for 20 cortical neuronal nuclei per subject. Because of the difficulty of estimating background fluorescence from brain sections, the results are not corrected for background. This approach provides a conservative estimate of the fold-reduction for MBNL1 in DM1 nucleoplasm.

Counts of 100 NeuN-positive cells from temporal and frontal cortex of 4 patients with classical DM1 (selected for best relative preservation of cortical architecture) showed RNA foci in >85% of cortical neurons in each case. More than one focus was visible in ~30% of cortical neurons, and occasional neurons had up to 15 small foci. In contrast, the individual having a small CTG repeat expansion (77 repeats) and mild phenotype (cataracts, mild weakness, and cognitive impairment after age 60 years) had foci in only 39% of NeuN-positive neurons in temporal cortex.

#### Example 10. FISH and IF analysis of other neuronal populations in DM1

RNA foci were widely distributed in other neuronal populations, including the hippocampus (all sectors), dentate gyrus, thalamus, and also the substantia nigra and brain stem tegmentum (each of 4 patients examined) (Fig. 13). The main exception was in cerebellar cortex, where small foci were detected in some Purkinje cells but not in neurons of the molecular or granular cell layers (n=6 patients examined) (Fig. 12D).

RNA foci were also present in the subcortical white matter and corpus callosum in occasional cells expressing 2'3'-cyclic nucleotide 3'-phosphodiesterase (CNPase), a marker for oligodendrocytes (Fig. 12E). However, these foci were smaller and less intense than those in cortical neurons. In sections processed on the same slide and imaged under the same exposure settings, quantitation of FISH signals indicated that the amount of CUG expansion RNA in frontal cortical neurons was 2.9-fold greater (area  $\times$  intensity) than in Purkinje cells ( $p < 10^{-10}$ ) and 18-fold greater than in oligodendrocytes ( $p < 10^{-10}$ ) within the same

individual (n=3 patients, 60 nuclei per patient).

#### Example 11. FISH and IF analysis of neuronal and muscle populations in DM1

Paired samples of frontal cortex and biceps muscle were available for three patients. When sections of skeletal muscle and cerebral cortex from same patient were processed on the same slide and imaged under the same exposure settings, the RNA inclusions were larger and more intense (3.1-fold greater, area  $\times$  intensity) in frontal cortical neurons than in skeletal muscle from the same individual ( $p < 10^{-10}$ , Fig. 14).

#### Example 12. Localization of mutant RNA

To determine if mutant RNA resides in a previously identified nuclear domain, mutant RNA was tested for colocalization with proteins that mark different nuclear compartments. These and subsequent experiments localizing protein relative to expanded poly(CUG) RNA were performed on a subset of 4 DM1 and 3 non-disease control samples showing the best preservation of cortical architecture. In contrast to nuclear inclusions of polyglutamine proteins (Skinner, P.J., Koshy, B.T., Cummings, C.J., Klement, I.A., Helin, K., Servadio, A., Zoghbi, H.Y., and Orr, H.T. (1997), *Nature*, 389, 971-974), RNA foci did not colocalize with PML bodies (Fig. 12F).

Colocalization of mutant RNA was likewise not found with the nucleolus (visualized by DNA staining or antibodies to C23 nucleolin), perinucleolar compartment (antibodies to polypyrimidine tract binding protein), or “speckles” (antibodies to hnRNP C) (data not shown). The possibility of colocalization with Cajal bodies cannot be eliminated, because p80 coilin antibodies did not consistently identify Cajal bodies in cortical neurons stained by the presently described methods.

#### Example 13. FISH and IF analysis of temporal and frontal cortical neurons

Recruitment of proteasome and exosome to nuclear RNA foci: the proteasome and exosome are multisubunit complexes responsible for protein and RNA degradation, respectively. To determine if these complexes are recruited to nuclear RNA foci, FISH analysis was combined with immunofluorescence using antibodies to components of the proteasome or exosome. Three components of the proteasome (20Sa, 11Sy and 11Sa subunits) were recruited to RNA foci in cortical neurons (Fig. 15A; Fig. 16A). No evidence was found, however, for ubiquitination or sumoylation of the foci (not shown). In contrast, antibodies to the PM/Scf75 or PM/Scf100 components of the exosome did not colocalize with RNA foci (Fig. 15B). This observation indicates that the proteasome may be recruited by conformational changes in MBNL1, MBNL2, or other poly(CUG) binding proteins. In such a case, loss of muscleblind function in DM1 may result from the combined effects of sequestration and accelerated degradation.

Monoclonal antibody 3B1 showed strong expression of CUGBP1 in cortical neurons (Fig. 15C). The distribution of this protein in neuronal nucleus and cytoplasm appears similar in DM1 patients and controls, and FISH/IF analysis shows that CUGBP1 is not recruited into RNA foci. Polyclonal antibodies to other members of the CUGBP1 family, ETR3 and CELF4, also fail to colocalize with foci (not shown). None of six different dsRNA binding proteins in neuronal nuclei (staufen, NF90, ADAR1, PACT, PKR, RNA helicase A)

colocalize with RNA foci (representative images for NF90 are shown in Fig. 15D and ADAR1 in Fig. 16B).

The RNA binding proteins hnRNP A1, hnRNP I, hnRNP M, KSRP and HuR did not colocalize with RNA foci (representative image for hnRNP M is shown in Fig 16D). In contrast, hnRNPs H and F colocalized with foci in cortical neurons to a limited extent (Fig. 15F, Fig. 16C), and these results were verified using two different polyclonal antibodies for each protein. The intensity of immunofluorescence for these proteins was greatest at the site of RNA foci; however, there did not appear to be significant depletion of hnRNP H or hnRNP F elsewhere in the neuronal nucleoplasm.

The splicing of neuron-specific exon N1 of *c-src*, which is promoted by hnRNPs H and F (Min, H., Chan, R.C., and Black, D.L. (1995), *Genes Dev.*, 9, 2659-2671; Chou, M.Y., Rooke, N., Turck, C.W., and Black, D.L. (1999), *Mol. Cell Biol.*, 19, 69-77) was not reduced in DM1 cerebral cortex. Indeed, inclusion of the N1 exon showed a slight (1.3-fold,  $p < 0.02$ ) increase in DM1 with respect to controls, opposite to the predicted effect of hnRNP F or H depletion (not shown). This fits with expectations that the number and density of binding sites on a single transcript, hence the capacity for protein sequestration, is much greater for proteins that bind to expanded poly(CUG) than for proteins that bind DMPK mRNA outside of the repeat tract.

Mutant *DMPK* mRNA is reported to interact with transcription factors retinoic acid receptor gamma (RAR $\gamma$ ) and Sp1 (Ebralidze, A., Wang, Y., Petkova, V., Ebralidse, K., and Junghans, R.P. (2004), *Science*, 303, 383-387). In cortical neurons, these transcription factors were readily detected by immunofluorescence but they did not colocalize with RNA foci (Figs. 15I and 16E) and their distribution was similar in DM1 patients and controls (Fig. 15I and 15J).

Polyclonal antisera recognizing all members of the muscleblind family (MBNL1, MBNL2, and MBNL3) showed strong colocalization with RNA foci (not shown). We used monoclonal antibodies raised against epitopes specific for MBNL1 or MBNL2 to determine which muscleblind proteins interact with CUG expansion RNA in neurons. MBNL3 was not examined because its expression in adults is mainly restricted to placenta (Fardaei, M., Rogers, M.T., Thorpe, H.M., Larkin, K. Hamshire, M.G., Harper, P.S., and Brook, J.D. (2002), *Hum. Mol. Genet.*, 11, 805-814; Kanadia, R.N., Urbinati, C.R., Crusselle, V.J., Luo, D., Lee, Y.J., Harrison, J.K., Oh, S.P., and Swanson, M.S. (2003), *Gene Expr. Patterns*, 3, 459-462). In normal controls, monoclonal antibody 3A4 showed expression of MBNL1 in nuclei and cytoplasm of cortical neurons (Fig. 15H).

In DM1, MBNL1 was strongly recruited into RNA foci, whereas staining elsewhere in the nucleus was markedly reduced (Fig. 15G). Quantitative analysis was performed on 3 DM1 patients and non-neurologic disease controls having the shortest postmortem intervals and best preservation of cortical architecture (Fig. 17). The mean immunofluorescence intensity for MBNL1 in the nucleoplasm (excluding RNA foci and nucleoli) was 2.3-fold lower in DM1 neurons than in non-disease controls ( $26 \pm 9$  area  $\times$  intensity units in DM1 patients vs  $61 \pm 17$  in controls, 20 neuronal nuclei per subject,  $p < 0.00001$ ). Monoclonal

antibody 2D9 showed that MBNL2 was also recruited into RNA foci (Fig. 15E). However, immunofluorescence signals in neurons with MoAb 2D9 were lower in relation to background staining in the neuropil, precluding a reliable quantification of its distribution. The finding of depletion of MBNL1 in the nucleoplasm of DM1 cells supports a model where CUG expansion RNA accumulates to levels sufficient to sequester and compromise the nuclear functions of MBNL1.

#### Example 14. DM1 and alternative splicing in the brain

To determine if DM1 is associated with altered regulation of alternative splicing in brain, 45 exons (in 31 genes) known to undergo alternative splicing in brain (Table 2, below) were examined.

Gene Name	Unigene	Alternatively Spliced Exon	Acc. No.	Nucleotides*
Amyloid beta (A4) precursor protein	APP	ex2	NM_000484	205-372
		ex7	NM_000484	1013-1180
		ex15	NM_000484	1181-1237
Actin-related protein 3-beta	ARP3BETA	ex2	BC008682.1	134-189
Beta-site APP-cleaving enzyme 2	BACE2	ex9	NM_012105	1448-1597
		ex10	NM_012105	1598-1766
Neuronal apoptosis inhibitory protein	BIRC1	ex10-11	NM_004536	1314-1453
Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit	CACNA1A	ex38	AF004883	5783-5879
Calcium/calmodulin protein kinase II dependent delta	CAMK2D	alt splice donor in ex21(44bp)	NM_172127	1709-1981
Clathrin light chain B	CLTB	exon cassette	NM_007097	641-694
Homo sapiens discs, large homolog 1	DLG1	ex8	NM_004087	771-824
Dopamine receptor type 2	DRD2	ex6	NM_000795	889-975
	EPB41L1	ex5	NM_012156	514-618

<b>Gene Name</b>	<b>Unigene</b>	<b>Alternatively Spliced Exon</b>	<b>Acc. No.</b>	<b>Nucleotides*</b>
Erythrocyte membrane protein band 4.1-like 1				
		ex21	NM_012156	2356-2439
GABA receptor alpha 2	GABRA4	ex3-8	NM_000809	345-1274
Gephyrin	GPHN	ex9	NM_020806	742-840
		ex12	NM_020806	976-1018
LIM domain binding 3	LDB3	ex10	AB 014513	918-1106
NMDA receptor NR1	GRIN1	ex5	AF015730	644-706
		ex20	NM_007327	3683-3793
		ex21	NM_007327	3794-3910
	NTRK2	exon cassette	AF410901	1878-1926
Neurotrophic tyrosine kinase, receptor, type 2				
C-Jun N-terminal kinase 2	JNK2	E6b, E6a	NM_002752	666-737
Netrin G1	Ntng2	E5	NM_032536	1115-1138
Neogenin	NEO1	ex26	NM_002499	3879-4037
Neurofibromin 1	NF1	ex9a	NT010799	108004- 108033
Neuronatin	NNAT	ex2	NM_005386	200-280
Neurorexin 1	NRXN1	ex3a	NM_004801	965-1024
		ex4		
		ex5		
		ex7a	NM_004801	1327-1250
		ex12	NM_004801	2540-2566
Neurorexin 2	NRXN2	ex12	NM_015080	2829-2855
		ex20	NM_015080	4197-4286
Neurorexin 3	NRXN3	ex12	NM_004796	1621-1647
NUMB	NUMB	ex8	AF015040	480-512
		ex15	AF015040	1367-1510
Presynaptic cytomatrix	PICO	ex10	AB011131	3056-3082

<b>Gene Name</b>	<b>Unigene</b>	<b>Alternatively Spliced Exon</b>	<b>Acc. No.</b>	<b>Nucleotides*</b>
protein				
Peanut-like 2	PNUTL2	ex2	NM_004574	189-579
Protein phosphatase 2, regulatory subunit B (PR 52), beta isoform	PPP2R2B	ex6	MN_181674	364-557
REST/NRSF/SBR	REST	ex5	AF228045	410-459
Microtubule-associated protein tau	MAPT	ex2	NM_005910	370-456
		ex10	NM_005910	1059-1151
Sarcolemma associated protein	SLMAP	ex4	NM_007159	273-395
	SRC	exon cassette	NM_005417	additional exon cassette (18bp or 50bp)
v-src sarcoma (Schmidt-Ruppin A-2) viral				
oncogene homolog (avian)				
* "Nucleotides" indicates which portion of the specified cDNA (GenBank accession number) was amplified by RT-PCR.				

Table 2. List of exons screened for abnormal regulation of alternative splicing in DM1 compared to control without neurologic disease. "Nucleotides" indicates which portion of the specified cDNA (GenBank accession number) was amplified by RT-PCR.

RT-PCR analysis of alternative splicing: total RNA was isolated from temporal cortex gray matter of 7 DM1 patients and 5 non-neurologic disease controls using TriReagent (Molecular Research Center, Cincinnati). cDNA was synthesized using SuperScript II reverse transcriptase (Invitrogen) with a mixture of oligo(dT)12-18 and random hexamer primers. The cDNA was digested with RNase H and then amplified using PCR primers flanking alternatively spliced exons (Table 2).

PCR products were resolved on agarose gels, stained with SybrGreenII (Molecular Probes), and analyzed on a fluorimager. An initial screen was performed on a subset of samples (4 DM1 and 2 control). Four exons appeared to show deregulated splicing in DM1. These differences were quantified in a second experiment including the full panel of 7 DM1 and 5 control samples. The fraction of exon inclusion was determined on triplicate reactions using ImageQuant software (Amersham, Piscataway).

For each exon, the ratio of inclusion versus exclusion isoforms was determined by reverse transcriptasePCR (RT-PCR) using primers flanking the regulated exon. An initial screen was performed using total RNA extracted from superior temporal cortex from two controls without neurological disease and four DM1 patients. Among 45 exons screened, 4 appeared to show a change in the ratio of exon inclusion/exclusion splice products in DM1. These differences were then confirmed and quantified in triplicate assays using temporal cortex RNA from 7 patients with DM1 and 5 controls (Fig. 18). DM1 was associated with decreased inclusion of amyloid precursor protein exon 7 ( $10 \pm 1\%$  in DM1,  $30 \pm 11\%$  in controls,  $p < 0.001$ ), increased inclusion of NMDA NR1 receptor exon 5 ( $33 \pm 11\%$  in DM1,  $11 \pm 5\%$  in controls,  $p < 0.01$ ), decreased inclusion of tau exon 2 ( $5 \pm 1\%$  in DM1,  $36 \pm 10\%$  in controls,  $p < 10^{-5}$ ), and decreased inclusion of tau exon 10 ( $21 \pm 1\%$  in DM1,  $41 \pm 5\%$  in controls,  $p < 10^{-6}$ ).

MBNL regulates fetal exon skipping in adults. The associated disease constitutes the failure in tissues to splice out specific fetal exons. Without MBNL, the fetal exons are retained. Other exons similarly regulated by MBNL remain to be identified.

Notably, DM1 is associated with reduced exon 10 inclusion (Fig 18), and FTDP-17 and DM1 are both associated with neurofibrillary tangles and neuronal aggregates of hyperphosphorylated tau (Foster, N.L., Wilhelmsen, K., Sima, A.A., Jones, M.Z., D'Amato, C.J., and Gilman, S. (1997), *Ann. Neurol.*, **41**, 706-715; Kiuchi, A., Otsuka, N., Namba, Y., Nakano, I., and Tomonaga, M. (1991), *Acta Neuropathol.*, **82**, 1-5; Yoshimura, N., Otake, M., Igarashi, K., Matsunaga, M., Takebe, K., and Kudo, H. (1990), *Clin. Neuropathol.*, **9**, 234-239; Vermersch, P., Sergeant, N., Ruchoux, M.M., Hofmann-Radvanyi, H., Wattez, A., Petit, H., Dwailly, P., and Delacourte, A. (1996), *Neurology*, **47**, 711-717).

Neuronal intranuclear inclusions are characteristic of several neurological disorders. In the polyglutamine disorders, the core component of the inclusion is mutant protein or a cleavage product containing the polyglutamine tract (Davies, S.W., Turnaine, k M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L., and Bates, G.P. (1997), *Cell*, **90**, 537-548; DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P., and Aronin, N. (1997), *Science*, **277**, 1990-1993). In Fragile X tremor ataxia syndrome (FXTAS), *FMR1* mRNA having an expanded CGG repeat leads to formation of nuclear inclusions (Greco, C.M., Hagerman, R.J., Tassone, F., Chudley, A.E., Del Bigio, M.R., Jacquemont, S., Leehey, M., and Hagerman, P.J. (2002), *Brain*, **125**, 1760-1771). The above-delineated results indicate that DM1 should be added to the list of disorders characterized by neuronal intranuclear inclusions.



Furthermore, in DM1 muscle tissue, evidence indicates that RNA inclusions are directly involved in disease pathogenesis, through a mechanism that involves sequestration of muscleblind proteins and mis-regulation of alternative splicing (Kanadia, R.N., Johnstone, K.A., Mankodi, A., Lungu, C., Thornton, C.A, Esson, D., Timmers, A.,M., Hauswirth, W.W., and Swanson, M.S. (2003), *Science*, 302, 1978-1980; Mankodi, A., Logigian, E., Callahan, L., McClain, C., White, R., Henderson, D., Krym, M., and Thornton, C.A. (2000), *Science*, 289, 1769-1773). The strong expression of expanded poly(CUG) RNA in DM1 neurons, formation of RNA inclusions, redistribution of muscleblind proteins, and altered regulation of alternative splicing shown above indicate that CNS symptoms of DM1 may also be triggered by RNA inclusions.

Despite evidence that mutant *DMPK* RNA accumulates to higher levels in cortical neurons (Fig. 14), the cell degeneration is more severe in muscle. The present results also indicate that splicing abnormalities are less frequent and less severe in cerebral cortex than in skeletal muscle (Fig. 18), suggesting that muscleblind proteins are more effectively sequestered in muscle nuclei, or that compensation for muscleblind deficiency is more effective in neurons, perhaps due to expression of additional RNA binding proteins. The exact determinants of cell vulnerability in DM1 are unknown, but the stoichiometry of CUG expansion RNA in relation to muscleblind proteins is likely to play an important role. Of note, while the present studies establish that the mutant *DMPK* mRNA is widely expressed in cortical and subcortical neurons, the failure to detect *DMPK* immunologically likely reflects its relatively low concentration in brain homogenates.

The 3-fold increase in the fraction of NMDA receptor 1 (NMDAR1) mRNA that includes exon 5 observed in DM1 brain is of significance, since inclusion of this exon influences the pharmacologic behavior, gating, and cellular distribution (somatic rather than somatodendritic expression) of NMDAR1 (Pal, R., Agbas, A., Bao, X., Hui, D., Leary, C., Hunt, J., Naniwadekar, A., Michaelis, M.L., Kumar, K.N., and Michaelis, E.K. (2003), *Brain Res.*, 994, 1-18).

NMDAR1 function is required for normal long term potentiation in the hippocampus and learning (Tsien, J.Z., Huerta, P.T. and Tonegawa, S. (1996), *Cell*, 87, 1327-1338). Thus, altered splicing of exon 5 may contribute to the memory impairment observed in DM1 (Rubinsztein, J.S., Rubinsztein, D.C., McKenna, P.J., Goodburn, S., and Holland, A.J. (1997), *J. Med. Genet.*, 34, 229-233).

Inclusion of tau exon 2 is reduced in DM1, confirming previous observations (Sergeant, N., Sablonniere, B., Schraen-Maschke, S., Ghestem, A., Maurage, C.A., Wattez, A., Vermersch, P., and Delacourte, A. (2001), *Hum. Mol. Genet.*, 10, 2143-2155). These results predict that fetal isoforms of tau (excluding exons 2, 3, and 10) are inappropriately expressed in adult DM1 brain, findings that correlate well with previous studies of tau protein in DM1 brain (Sergeant, N., Sablonniere, B., Schraen-Maschke, S., Ghestem, A., Maurage, C.A., Wattez, A., Vermersch, P., and Delacourte, A. (2001), *Hum. Mol. Genet.*, 10, 2143-2155).

Expression of human fetal tau in transgenic mice leads to formation of neurofibrillary tangles and axonopathy (Ishihara, T., Zhang, B., Higuchi, M., Yoshiyama, Y., Trojanowski, J.Q., and Lee, V.M. (2001), *Am. J. Pathol.*, 158, 555-562). It is unclear, however, whether the extent of the tau missplicing in DM1 is sufficient to cause neuronal dysfunction. Together with the above-described finding that DM1 is associated with increased expression of fetal splice isoforms for APP (exon 7 exclusion products), it is indicated that accumulation of mutant *DMPK* mRNA in the neuronal nucleus compromises a specific developmental program of alternative splicing.

The methods, techniques and compositions disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been illustrated with several examples and preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and compositions, in the steps or in the sequence of steps and in modifications of the compositions without departing from the concept, spirit and scope of the invention. Accordingly, the exclusive rights sought to be patented are as described in the claims below.

## ADDITIONAL SEQUENCES

### SEQ ID NO: 1

Mus musculus muscleblind-like 1 (*Drosophila*) (*Mbnl1*), mRNA.

ACCESSION NM\_020007

(bases 1 to 5588)

### ORIGIN

```
1  ggcgacatgc cacagtctct cgccgcagcc cgtcgagtcg gggcgctcgc catgtcccg
61  tgacccggac ccggccagtt cctttcccg tggcgggcat cccggagtcg cgatcccaca
121 atgccccggg cagtcggggc cccggcgggc agcctgcacg gccacgtgag aggttggtac
181 taagaagtgc ctttctgac gtctctgctg ctggaaccg cttctagagc agcctctgct
241 ttgccttgc ttgctccag ctagactgac gacagcacat ccgcctcca cctctagccc
301 agacacccca ttctacttc taatcaggag aaaagctctg agtatctgcc attgccttag
361 gctgctttag tttagaagaa aagtttgctg aaaaagtaag ataccttctg ccaggaaatc
421 aaggaggaaa aaaaaaatc attttctga tttgtctta aactgctgca tctgtctatg
481 ccaaaactat caataccgat tgcaccacca aactccatcg caaatcagct gtgaggagat
541 tccctgtcag acaactttgc tgaaagcagc ttggaaatc ggtgtcaaag ggtctgccac
601 gttttatgc ttgcattttg ggctccaaat tggcactggg aaggggttac tgagcacacg
661 gctgagtcca ggcctctct aaacacccat ctacttacag tcttggtatt cctctcaaaa
721 ccaaaacctc ttgaattaa cagtttcatg ctgtgaattt ctageggagg tctttccctt
781 tatattgaag tcacactttt ccatgtgccg ttaaatcggg gacgggggaa gcagcctttc
841 ggacattttc acagttatct cacactctga gttttatcag ttcctatttt gtttagtttt
```

901 tgtcttttgt ttggttgct gattttttt ttctatttt cttttcttt ttctttctt  
 961 tttttcttt ttgttttcc tttttttt ttggagagg ggttgggtt gtggtttca  
 1021 tgaacattt aactacctgt aaaatataaa catggctgtt agtgcacac caattcggga  
 1081 cacaaatgg ctaacctgg aagtatgtag agagttcaa agggggactt gctcacgacc  
 5 1141 agacacggaa tgtaaattg cacatcctt gaaaagctgc caagtgaat atggacgagt  
 1201 aatcgctgc ttgattcac tgaaaggtcg ttgctccaga gagaactgca aatatctca  
 1261 tccaccccca cacttaaaaa cacagttaga gataaatggg cggaataact tgattcagca  
 1321 gaagaacatg gccatgctgg ccagcaaat gcagttagcc aatgccatga tgcccgtgc  
 1381 cccgttgtag cccgtgcca tgtttctagt tgcaccaagc ttagccacca gtgcatcagc  
 10 1441 agcctttaac cctacctgg ggcctgttc cccaagcctg gttccagcag agatcttgc  
 1501 gactgcacca atgttggtca cggggaatcc tggagttcca gtgccagcag ctgccgcagc  
 1561 tgctgcacag aagttaatgc ggacagacag actggaggtg tgcgagagt accagcgtgg  
 1621 caattgcaac agaggagaaa atgactgtcg gtttctcat cctgctgaca gcacaatgat  
 1681 tgatacaat gacaacacag tctactgtcg catggattac atcaagggga gatgctctg  
 15 1741 ggaaaagtgc aaatacttc atctccgc acacctgca gccaagatca aggtgccca  
 1801 ataccagtc aaccaggtg cagcagcaca ggctgcagt actgcagctg ccatgggaat  
 1861 tctcaagct gtactcccc cattgcaaaa gaggcctgt cttgaaaaa ccaacggtgc  
 1921 caccgcagtc ttaacactg gtattttcca ataccaacag gctctagcca acatgcagt  
 1981 acagcagcat acagcattc tcccaccagg ctcaatattg tgcagacac ccgtacaag  
 20 2041 tgttgttccc atggtgcag gtgctagcc agccactgt tccgcagcaa caacatctgc  
 2101 cacaagtgt ccttctgtg caacagccac agccaaccag ataccataa tatctgccga  
 2161 acatctgact agccacaagt atgttaccga gatgtagagc tgcgtcaca aaacaatcat  
 2221 acaaagagga aaggacagtg tcttgatta gattaaggac gacgtcatta gccatattg  
 2281 atatacgtc aagcaacaca taaaaaatc ctcagccac aagacatcca catattgcat  
 25 2341 gtaaccaga agaaacgaca acatgggaac ctgctgcaca ctgttgcta cacacttgt  
 2401 acattcagtt ggtattgtg ctgaggtgat attcctatct aaaacaaca cattgtctt  
 2461 ctttttagc acagagttat gcattaaaat atgcatact aattagttc ctatatatt  
 2521 atgcatctt gaaaagacag actatggtg gaccatgatt ctattatga ttgtacgtc  
 2581 ttagaccaa gatataatt ttaaaaaata agttatttc ttcaaggt tacaagtaac  
 30 2641 caaggtgcac ctgtattta aaatgccgt tagagctgag agcgcgcatg cagagtcatt  
 2701 tttgttgag agtaatttt ttactgtaat agattgtacg acatggtgag ggagggaact  
 2761 gacagatgaa tgtgccaagc aaaaccacaa ctgtgtatat tttaaagcac accatggctt  
 2821 taagtacat gttgtaagg atttcatga agtccatag actgtacac aaattagagt  
 2881 attattctt cagtgtatt gttctggag ccacatttg ttgctattt gctagtacta  
 35 2941 atcaatcaaa gggcaccatt cttttcttt ttgttttga aaccaaagct gtctcagaaa

3001 tggccaattt aactttacag taacaataga cagcacaaca caaactcaat acagataacc  
 3061 ttccacatac tggagatata tatgatagat atataaaatt attttaatgc attgtagtgt  
 3121 aatatttatg catactctac tatataacat gttattcaaa agggatatgc catttctgag  
 3181 acacaataac aaaaaatggt tgaggaaatt attttgcttc tatttatagc ctctgtcaaa  
 5 3241 agtcaaaaga ctataaatgc ttgcagaaa tgggttcacg ttgcttaaa cgcttcatca  
 3301 cagtcacatt caaaatagtg actctaaaca aagagaacag cactgtcatc agatgcatga  
 3361 taaacaaaa tatgaaaatg ggaaatgttt aattaaccta gtaattgggt gggttaagta  
 3421 catgggtgaa ttttatatgt gattctttt ttcagattaa ctgcttatag ccttagaaag  
 3481 ccttttaaaa aattttaaaa atagatgtgc attcagttt taagaatgga ttcacccaaa  
 10 3541 ggaattcccc tttttgtgg ttggatgtt gcagctagga aaggctattt ttgctctgtt  
 3601 cagcagttct aaaatcgctg agtaggggcc aggtcactgg cagttctagt gtggaatggg  
 3661 agaagtgaga gttctgttat agaactttcc atacttccaa gtttactgca agttttatg  
 3721 cttgagagag atgctttcta atataagact gatgtgttga ttttctgat tgtactgtac  
 3781 atctattaaa gccttagatt attacattac ggggttgaac ccataccaat gtaatttcaa  
 15 3841 tcgtgttaag agagtaatgg tgacttcaca tgttattgta gttagtacg ttatagaata  
 3901 ttacttattt ttctgttaa aatgtagttt ttcatttctt acattattg gattttcatt  
 3961 ttctattaac agttgaatac catttcagtt ttagactat tgttttatta gattttacca  
 4021 atgaattttt caaaatacaa aaaaattaaa gtagttttt ctccataaca tactcagttt  
 4081 taaattacat gtagtgtcat atgaatatcc gtattattgt taactaaatg atttatattt  
 20 4141 tactgattta atattacagt gtaagaatgt cagtcattgt tctgtctag ttttcattaa  
 4201 aagaacaaag atcttttata tggatatctt ataaatata atcattgct aagtaagaag  
 4261 ttaagtgtt gctatggcaa caatcctggc agacaattga gtaatatatt gatgatttat  
 4321 tttgtttgta attagtatt atgagaagat ctagatccta gatattagaa taaaatttat  
 4381 ttttactgt atccatttca aatgttaaag tattgtttaa ttttttgaa atccctgaat  
 25 4441 atcaggcctt gttataaata agctgcataa tcaataaata gaacaaggga cttttgttg  
 4501 ataaccaaa tactcaaatg ttacgtaatg agaatttag cgtgtgtgca aactctgag  
 4561 ggttgatgat gctgcaatt agcatgttg aaagtctaga gagaagggtg acttttgca  
 4621 ctctgtata tagtcaaaag agagaaacct gtataatagc aagatcttat ttgaataaa  
 4681 aacgtctata attacaagga gttttgttaa ggctaagaa atgacagact gagcaaaatt  
 30 4741 gcttgcaaaa gtggcacaga gttagcact cataccctc aaacacgtcg ctttgcttt  
 4801 tgtggacagc tttagtttg ccaggattt tcagctggaa agatttgcca tcttccaag  
 4861 atctcatgac tgacaaaact ccattgggcc aaatctgct gaagatcatt accaaaaaat  
 4921 agcaggtagt tcagccacta agatgaaatc atggatcaga tatcccttac attgtttca  
 4981 aaactactgc atgtttaaaa ctcaacaaa aagagagaaa gaactatgct aaggacatat  
 35 5041 attattcaga tcgatatcta ccaatttcag tggttaatg ttcacaaaat gaaatcttga

5101 aaataactat tgactttcac aaaattftaa ccataaacag gcaaaccaaa cagcacacct  
 5161 gtagttgttc tgtgattgtt tttaattgc ttagatcat gttcttccg cagggtgaaa  
 5221 aaaaaaaaaa aaaaaaaaaa gaagttcaaa tttcacagt ttaatttca actcagaagc  
 5281 aaaagagcaa aatgtgacaa tggccacttg ttaatgact tggttgccca gctgtcactg  
 5341 cagctggcta ctgatgttgc acttaccagc aaccaccca cttcatctg ccgaaaggac  
 5401 agtgagcttg gttttacgat tatgtaatca caacttact tctgcttga gtggcttaaa  
 5461 attatgtatt ttgtctaggg ctgcaatttg tttatgctt actttattat tactgcagta  
 5521 gttgactttg ctgtatggaa aaataaagcg aaattgccct aataaaactt ctctttctta  
 5581 agtaaaaa

SEQ ID NO: 2

Mus musculus muscleblind-like 2 (Mbnl2), transcript variant 2,  
 mRNA.

ACCESSION NM\_207515

(bases 1 to 4527)

ORIGIN

1 agcagtggta acaacgcaga gtacgggggg tgggaaggaa gggctgcagc tcacagcaac  
 61 agagtttaga ctgtctttgc ttcacatct gaaggtaaaa tttccagcc acggccggcg  
 121 gctgcagag tacaataaac agggacggag aactatttg atggaccccc ctctctatg  
 181 atgcggtgga gaagccacgg ccactcggtc ctgccagatg ttctgggggt tactgtacat  
 241 ggggaagacg agcagagcta aacaagaatt taaagaggac gaaggaagga aagcgccatc  
 301 ctgctcaaat acaaatgctt aagagggttg tttccaca tctccaaag ctgtgagcat  
 361 tagaactaat attttccaa agagtgccat cgtattaaag ccactttatt aaggaggggt  
 421 gtatctgcaa aacagtcaag agactagaac cctgggagcc agagatgaca gtgagcacgc  
 481 actgcttggt gctcacagtc ttccagtggg gcctatcgt cgggtactga ctctctgctt  
 541 gctgacacat tccccctccc cggtttctg gattggactg cattaaagaa ttcactgctt  
 601 accttcaaac ttacatgttg gagttttcac ggcggttgtt ttgagatcat tgagactcgg  
 661 attgatttcg acatttaacc gaaaggaaca gagcccaaag tagttctcat catggccttg  
 721 aacgttgccc ccgtgagaga cacaagtgg ctgacgctgg aggtctgcag acagtaccag  
 781 agaggaacgt gctcacgctc cgacgaagaa tgcaagtttg ctcaccccc caaaagttgc  
 841 caggttgaat atggaagagt aattgcctgc ttgattccc tcaagggccg ctgttcaaga  
 901 gagaactgca aatatcttca tctccgaca cacttaaaaa ccagctaga gattaatggg  
 961 aggaacaatt tgatccagca aaaaactgca gcagcgatgc tgcccagca gatgcaattt  
 1021 atgtttccag gaacgcgct ccatcctgtg cccacttttc ctgtaggtcc caccataggg  
 1081 acaaatgcgg ctattagctt tgctccttac ttagcgctg tcaccctgg agttgggtta  
 1141 gtcccaacag aggttctacc cactacaccg gtcattgttc ccggaagtcc accggtcact

1201 gtccccgggct caactgcaac tcagaaactt ctcaggactg ataaactgga ggtatgcagg  
 1261 gagttccagc gaggaaactg tgccccgggga gagacagact gccgctttgc acacccggca  
 1321 gacagcacca tgatcgacac aaacgacaac accgtaaccg ttgtatgga ttacataaag  
 1381 gggcggttga tgaggagaaa atgcaaatat ttccaccctc ctgcacactt gcaggccaaa  
 5 1441 atcaaagctg cgcagcacca agccaaccag gccgcggtgg ccgcccaggc agccgcggcc  
 1501 gcggccacag tcatggcctt cctccgggt gctcttcac cttaccaa gagacaagca  
 1561 cttgaaaaaa gcaacggggc cagcacggtc ttcaaccca gcgtcttga ctaccagcag  
 1621 gctctgacca gtgcgcagct gcagcagcac acggcggtca tccccacagt acctatgatg  
 1681 cacagcgcta cgtccgccac tgtctctgca gcaacaactc ctgcaacaag tgtcccctc  
 10 1741 gcagcaacag ccacagccaa tcagataatt ctgaaataat caacagaaat ggaatggaat  
 1801 gccaagaatc tgcattgaga ataactaaac attgttactg tacatattac cccgtttcct  
 1861 cctcaataga attgccaaa actgcatgct aaatttagtt cttctggaca gaccacaacc  
 1921 ctaaggctag ttctgctatg tcatatatga gtattaaata tggatgctt agtatactcc  
 1981 agcctaagat agttaaccac ctgagaccag ctgtgatgtt cgaagacata caggatgagg  
 15 2041 tttctttca cagggttctg agcatagttt ctgtcccagg aatattgtct tatctccata  
 2101 actatagctg atgcagaaag tccagacaa atactcattt cgactcagaa tatttcaaat  
 2161 tttagcaata acagttagct ttagtttta gtacctattc caagggcagg ttcgattgta  
 2221 actccaatca caaccatttc atttctgac tggatcgaag ggtatgattc acttcttgag  
 2281 gagacggaca gtcgcagcag agagaagtga agtaaaacat acgcctgcct cgcaggtcta  
 20 2341 aagtctgagt ggcagctcaa gcacaattgc caggggacac atcagagtgt ggggttcgct  
 2401 ttgccaggag atgccgcact gaatcatggg attctagaat aacattgcat agattgaaaa  
 2461 aaaaaaaaaa actttgcacg gtatgagctt catacccaac ccaacaaagt cttgaaggta  
 2521 ttattttaca agtatatttt taaagttgtt ttataagaga gactttgtag aagtgcctag  
 2581 attttgccag acttcatcca gcttgacaag aatgaaaggc tcatgccaat agtcgaatct  
 25 2641 aagggttggt tctttcaaac tcgccctccg gttgcctgtt accgaataac tcttcaaac  
 2701 taaaacctag tcaaacaggg aagctgtagg tgaggaggtc tgtataatat tccagtttaa  
 2761 gtacgtctga gtttagtcac tacagatgca aactgtgact ttaatctaaa ttactatgta  
 2821 aacgaaaaaa aaaagtagat agtttcaact tttaaaaact ccattactgt tttgcattt  
 2881 taagagttgg attaaagggt tgtaagtaac tgcagcatgg aaaaatagtt cttttaattc  
 30 2941 tttcacctta aagcatattt tatgtctcaa aagtataaaa aactttaata caagtacaca  
 3001 catattatat atacacatac atatatatac tatatatgga tgaaacatat tttaatgttg  
 3061 ttacttttt ttaataactt ggttgatctt caaggtaata gcgatacaat taaattttgt  
 3121 tcagaaagtt tgttttaaag tttattttaa gcactatcgt accaaatatt tcatatttca  
 3181 cattttatat gttgcacata gcctacacag tacctacata gtttttaaat tattgtttaa  
 35 3241 gaaatgaaac agctgttata aatggatatt atgtgtaatt gtttaaaaca tccattttct

3301 ttgtgaacat ttagtgatt gaagtattt gacttttgag attgaatgta aaatatttta  
 3361 aattttggta tcatgcctg ttctgaaaac tagaggcatc caaccatata atttttttg  
 3421 attgaaaaaa gatctgcatt taattcatgt tggtaaagt ctaattacta ttatcttac  
 3481 atcatagatc tgataactgt atcgaaaaga gaaatcacat tctgagtga atcttgcata  
 5 3541 gtgcttgtgt cgtgtttgtt tttaattgt ggaaaggat tgatctaac ttgatcacc  
 3601 ttgatagttc tcactttat gtattattga tatttgaat ttctcagct ataacaatgt  
 3661 agttacgcta caactgcct aaaacactca tactttttt ttctttact tactcatta  
 3721 aactcattga gaagatagta gactaaaaag gtaaattatg ggaatcactg aaatatttt  
 3781 gtagactaat tgttgtaact gtcctttctt ctttcattt catgatttt atttataaa  
 10 3841 ttattagcac atagctattt tcagccctt aataactgat catcaaaaca tcacctgtat  
 3901 cccccagcca atagatagta ctgtatttt tactatgata tccattttc agaattgtga  
 3961 ttataatatg cagagtcaaa tatgccattt acaataagga ggaggccagg caaatgcata  
 4021 gatgtacaaa tatatgtaca acagatttg cttttattt attataatg taattttata  
 4081 gaataattct gggatttgag aggatctaaa actattttt tgtataaata ttatttgcca  
 15 4141 aaagtttgtt tatattcaga agtctgacta tgatggataa atctaaatg cttgtttta  
 4201 ttacaaaaac aaaatcacca atatcaaga caggaagatc tcagttcaac agtcccgta  
 4261 gttagggaac taactccact tgcacaggac ttcatctac tcttggttt caggctataa  
 4321 cagcacttca cagaactatt cttcagcca tacaccactg gtcacattc tactaaatct  
 4381 ttctgtaaca cttctaaag aattccctca ttcgttatct tacagtgtaa acaggactct  
 20 4441 aatttgtatc aattatatgt ttggttgta atattcagtt cactcaccca atgtacaacc  
 4501 aatgaaataa aagaagcatt taaaagg

# SEQ ID NO: 3

Mus musculus muscleblind-like 3 (Drosophila) (Mbnl3), mRNA.

ACCESSION NM\_134163

25 (bases 1 to 1967)

## ORIGIN

1 ctgaaggatc acgtaactca gaaaatctaa aacacattat gtgtccaaat cagttcttct  
 61 gaggtagcgc gacgcgtggg ttacacgacg caagtgcgtc ctacaggaag aaagtgcctc  
 121 cagtcggagc gcgagcagga gcgcgacttt ttggcgctct ttgcgagcga gccgcaagga  
 30 181 ggcggaagac ggtcccgggc cggggcgcgg gaatcggggc agcgagcgcc gcacggggga  
 241 gttcctgcgc gtggcgctct cgcagcgaga cgccgctgga gtcgctact cggagagatt  
 301 cttgaacca tctgcagtca taatattctc tgaagagggt gcacttgatt gccaatgtgc  
 361 tctcagtatg acacctgtca atgtagctct aatccgtgat accaagtggc tgactttaga  
 421 agtctgtaga gaatttcaga gaggaacttg ctctcgagct gatgcagagt gcaggtttgc  
 35 481 ccatccgcca agagtttgc atgtggaaaa tggccgagtg gtggcctgtt ttgattcact

541 aaagggtcgg tgcactcgtg agaactgcaa gtacctccac cctccaccgc acttaaagtc  
 601 gcagctagaa gttaatggga gaaacaatct gattcaacag aagactgccg cagccatggt  
 661 cgcccagcac atgcaactca tgctgcagaa cgctcagatg tcattcttgg cgtcttttcc  
 721 tatgaatcca tcaattgcag ctaatcctgc catggcttcc aatccttaca tgactcatcc  
 5 781 tggcatgggc ctggttctg ctgagctttt accaaatggg ccggttctga ttcttgaaa  
 841 ccctctctt gcactgccag gatttcttgg tccaaagcca attcgtacag atagactgga  
 901 ggtttgccgt gaatttcagc gtggaaattg tacccgtggg gagagcgagt gccgctatgc  
 961 tcacctacg gatgtttcca tgattgaagt cactgataat tctgtgacaa tctgcatgga  
 1021 ttacattaaa ggccgatgct cccgggagaa atgcaagtac ttcatcctc ctccccactt  
 10 1081 gcaggccaaa ctcagggcag ctcatcacca gatgaacct tctgtgcca atgcaatggc  
 1141 cctgccgcat ggtgcacttc aactgatacc aaagagggtc gcccttgaca aggccaatgg  
 1201 tgccactcca gtcttaacc ccagtgtttt ccaactgcaa caggctctgg ctaacatgca  
 1261 gattctcag caggctttta tccaacagt gcccatgatg cacggtgcta caccttccac  
 1321 tgtgtctaca gcaacaccac ctgccagcaa cgttccctac gtccaacaa ctacaggcaa  
 15 1381 ccagttgaaa tattgagcag cagagttaca gattatcaga atctctcaac aagaaactcc  
 1441 gtgtggcctt tctatatga ttctgtatg tcttctgta ccaacacgac aataagcatg  
 1501 gtgcagtcaa tataactaaag cgcataatcc tgttgacaaa ttcaaatttt aaaaatctgt  
 1561 ggagatgta aagcaaatag aaaattaacc agtatgtgtt acctatagc gattcattgt  
 1621 atatgaatta gcatacaata tacaaccata caggtttgtc atgtatatga attatcagat  
 20 1681 ccatattaca tgaatttcc atatgatag aattaccata ttgaatataa ctgtaaaatg  
 1741 ttgtgactgc ttccagtaa tgggtttataa taaatgaact tccacagtgt actgtaggct  
 1801 tactgtatac tcttggtgga taaattctgt ttggaagtgt ttacctact gttttgtta  
 1861 caagatagtc tataggattg atgtagaatg taactgatat tccccacacc attttcctcc  
 1921 attggtatat tgtattaaat tgggttctgc ttaaaaaaaaa aaaaaaa

25 SEQ ID NO: 37

Homo sapiens amyloid beta (A4) precursor protein (protease  
 nexin-II, Alzheimer disease) (APP), transcript variant 1, mRNA.

ACCESSION NM\_000484

(bases 1 to 3641)

30 ORIGIN

1 gctgactcgc ctggctctga gcccgcgcgc cgcgctcggg ctccgtcagt ttctcggca  
 61 gcggtaggcg agagcacgcg gaggagcgtg cgcggggggc cgggagacg gcggcggtgg  
 121 cgccgcgggc agagcaagga cgcggcggat cccactcgca cagcagcgca ctcggtgccc  
 181 cgcgcagggt cgcgatgctg cccggtttgg cactgtcct gctggccgcc tggacggctc  
 35 241 gggcgctgga ggtaccact gatggaatg ctggcctgct ggctgaacct cagattgcca



301 ttgtctgtgg cagactgaac atgcacatga atgtccagaa tgggaagtgg gattcagatc  
 361 catcagggac caaaacctgc attgatacca aggaaggcat cctgcagtat tgccaagaag  
 421 tctaccctga actgcagatc accaatgtgg tagaagccaa ccaaccagtg accatccaga  
 481 actggtgcaa gcggggccgc aagcagtga agacccatcc ccactttgtg attccctacc  
 5 541 gctgcttagt tggtagttt gtaagtgatg cccttctcgt tctgacaag tgcaaattct  
 601 tacaccagga gaggatggat gtttgcgaaa ctcatcttca ctggcacacc gtcgcaaag  
 661 agacatgcag tgagaagagt accaacttgc atgactacgg catgttgctg ccctgcggaa  
 721 ttgacaagtt ccgaggggta gagtttgtgt gttgccact ggctgaagaa agtgacaatg  
 781 tggattctgc tgatgcggag gaggatgact cggatgtctg gtggggcgga gcagacacag  
 10 841 actatgcaga tgggagtga gacaaagtag tagaagtagc agaggaggaa gaagtggctg  
 901 aggtggaaga agaagaagcc gatgatgacg aggacgatga ggatggtgat gaggtagagg  
 961 aagaggctga ggaaccctac gaagaagcca cagagagaac caccagcatt gccaccacca  
 1021 ccaccaccac cacagagtct gtggaagagg tggttcgaga ggtgtgctct gaacaagccg  
 1081 agacggggcc gtgccgagca atgatctccc gctggtactt tgatgtgact gaagggaagt  
 15 1141 gtgccccatt cttttacggc ggatgtggcg gcaaccggaa caactttgac acagaagagt  
 1201 actgcatggc cgtgtgtggc agcgccatgt cccaaagttt actcaagact acccaggaac  
 1261 ctcttgcccg agatcctgtt aaacttcta caacagcagc cagtaccctt gatgccgttg  
 1321 acaagtatct cgagacacct ggggatgaga atgaacatgc ccatttcag aaagccaaag  
 1381 agaggcttga ggccaagcac cgagagagaa tgtcccaggt catgagagaa tgggaagagg  
 20 1441 cagaacgtca agcaaagaac ttgcctaaag ctgataagaa ggcagttatc cagcatttcc  
 1501 aggagaaagt ggaatctttg gaacaggaag cagccaacga gagacagcag ctggtggaga  
 1561 cacacatggc cagagtggaa gccatgtca atgaccgccg ccgcctggcc ctggagaact  
 1621 acatcaccgc tctgcaggct gttctctctc ggctctgta cgtgttcaat atgctaaaga  
 1681 agtatgtccg cgcagaacag aaggacagac agcacacctt aaagcatttc gagcatgtgc  
 25 1741 gcatggtgga tcccaagaaa gccgctcaga tccggtccca ggttatgaca cacttcctg  
 1801 tgatttatga ggcgatgaat cagtctctct ccctgctcta caactgcctt gcagtggccg  
 1861 aggagattca ggatgaagtt gatgagctgc ttcagaaaga gcaaaactat tcagatgacg  
 1921 tcttgcccaa catgattagt gaaccaagga tcagttacgg aaacgatgct ctcatgcat  
 1981 ctttgaccga aacgaaaacc accgtggagc tccttcccgt gaatggagag ttcagcctgg  
 30 2041 acgatctcca gccgtggcat tctttgggg ctgactctgt gccagccaac acagaaaacg  
 2101 aagttgagcc tgttgatgcc cgccctgctg ccgaccgagg actgaccact cgaccaggtt  
 2161 ctgggttgac aaatatcaag acggaggaga tctctgaagt gaagatggat gcagaattcc  
 2221 gacatgactc aggatatgaa gtatcatc aaaaattggt gttctttgca gaagatgtgg  
 2281 gttcaacaa aggtgcaatc attggactca tgggtggcgg tgtgtcata gcgacagtga  
 35 2341 tcgtcatcac cttggtgatg ctgaagaaga aacagtacac atccattcat catggtgtgg

2401 tggagggtga cgccgctgtc accccagagg agcgccacct gtccaagatg cagcagaacg  
 2461 gctacgaaaa tccaacctac aagttctttg agcagatgca gaactagacc cccgccacag  
 2521 cagcctctga agttggacag caaaaccatt gcttcactac ccatcgggtg ccatttatag  
 2581 aataatgtgg gaagaaacaa acccgtttta tgatttactc attatcgctt ttgacagct  
 5 2641 gtgctgtaac acaagtagat gcctgaactt gaattaatcc acacatcagt aatgtattct  
 2701 atctctcttt acattttggt ctctatacta cattattaat gggttttgtg tactgtaaag  
 2761 aatttagctg tatcaaaacta gtgcatgaat agattctctc ctgattattt atcacatagc  
 2821 cccttagcca gttgtatatt attctgtggg ttgtgaccc aattaagtc tactttacat  
 2881 atgctttaag aatcgatggg ggatgcttca tgtgaacgtg ggagttcagc tgcttctctt  
 10 2941 gcctaagtat tccttctctg atcactatgc attttaaagt taaacatttt taagtatttc  
 3001 agatgcttta gagagatttt tttccatga ctgcatttta ctgtacagat tgctgcttct  
 3061 gctatatttg tgatatagga attaagagga tacacacgtt tgtttcttcg tgcctgtttt  
 3121 atgtgcacac attaggcatt gagacttcaa gcttttcttt tttgtccac gtatctttgg  
 3181 gtctttgata aagaaaagaa tccctgttca ttgtaagcac tttacgggg cggttgggga  
 15 3241 ggggtgctct gctggtcttc aattaccaag aattctccaa aacaatttc tgcaggatga  
 3301 ttgtacagaa tcattgctta tgacatgac gctttctaca ctgtattaca taaataaatt  
 3361 aaataaaata accccgggca agacttttct ttgaaggatg actacagaca ttaaataatc  
 3421 gaagtaattt tgggtgggga gaagaggcag attcaatttt cttaaccag tctgaagttt  
 3481 catttatgat acaaaagaag atgaaaatgg aagtggcaat ataaggggat gaggaaggca  
 20 3541 tgcctggaca aaccttctt ttaagatgtg tctcaattt gtataaaatg gtgttttcat  
 3601 gtaaataaat acattcttgg aggagcaaaa aaaaaaaaaa a

SEQ ID NO: 38

Homo sapiens NMDAR1 subunit isoform 3b (hNMDAR1-3b) mRNA, complete  
cds.

ACCESSION AF015730

5 (bases 1 to 3150)

ORIGIN

```

1 aagcttatcg atccgtcgac ctgagggggg ggcccgcgtt cgccgcgcag agccaggccc
61 gccgggcgag cccatgagca ccatgcgcct gctgacgctc gccctgctgt tctcctgctc
121 cgtcgcccgt gccgcgtgcg accccaagat cgtaacatt ggcgcggtgc ttagcacgcg
10 181 gaagcacgag cagatgttcc gcgaggccgt gaaccaggcc aacaagcggc acggctcctg
241 gaagattcag ctcaatgcc cctccgtcac gcacaagccc aacgccatcc agatggctct
301 gtcggtgtgc gaggacctca tctccagcca ggtctacgcc atcctagtta gccatccacc
361 taccccaac gaccacttca ctcccacccc tgtctctac acagccggct tctaccgcat
421 acccgtgctg gggctgacca cccgcatgtc catctactcg gacaagagca tccacctgag
15 481 ctctctgctc accgtgccgc cctactccca ccagtccagc gtgtggtttg agatgatgcg
541 tgtgtacagc tggaaccaca tcctctgct ggtcagcgac gaccacgagg gccggggccg
601 tcagaaacgc ctggagacgc tgctggagga gctgagtc aagagtaaaa aaaggaacta
661 tgaaaacctc gaccaactgt cctatgacaa caagcgcgga cccaaggcag agaaggtgct
721 gcagtttgac ccagggacca agaactgac ggccctgctg atggaggcga aagagctgga
20 781 ggccgggtc atcatccttt ctgccagcga ggacgatgct gccactgtat accgagcagc
841 gcgcatgctg aacatgacgg gctccgggta cgtgtggctg gtcggcgagc gcgagatctc
901 ggggaacgcc ctgcgttacg ccccgagcgg catctcggg ctgcagtc tcaacggcaa
961 gaacgagtcg gccacatca gcgacgccgt aggcgtggtg gccagggcgg tgcacgagct
1021 cctcgagaag gagaacatca ccgacccgcc gcggggctgc gtgggcaaca ccaacatctg
25 1081 gaagaccggg ccgtcttcca agagagtct gatgtcttcc aagtatgcgg atggggtgac
1141 tggtcgctg gagttcaatg aggatgggga ccggaagtc gccactaca gcatcatgaa
1201 cctgcagaac cgcaagctgg tgcaagtgg catctacaat ggacccacg tcaccttaa
1261 tgacaggaag atcatctggc caggcggaga gacagagaag cctcgagggt accagatgtc
1321 caccagactg aagattgtga cgatccacca ggagcccttc gtgtactca agcccacgt
30 1381 gagtgatggg acatgcaagg aggagtac agtcaacggc gaccagtc agaaggtgat
1441 ctgcaccggg cccaacgaca cgtcgccggg cagccccgc cacacggtgc ctgagtgtg
1501 ctacggcttt tgcacgacc tgctcatcaa gctggcacgg accatgaact tcacctaga
1561 ggtgcacctg gtggcagatg gcaagttcgg cacacaggag cgggtgaaca acagcaaca
1621 gaaggagtgg aatgggatga tgggcgagct gctcagcggg caggcagaca tgatcgtggc
35 1681 gccgctaacc ataaacaacg agcgcgcgca gtacatcgag tttccaagc cttcaagta
```

1741 ccagggcctg actatgctgg tcaagaagga gattccccgg agcacgctgg actcgttcat  
 1801 gcagccgttc cagagcacac tgtggctgct ggtggggctg tcggtgcacg tggtagccgt  
 1861 gatgctgtac ctgctggacc gttcagccc ctccggccgg ttcaaggtga acagcgagga  
 1921 ggaggaggag gacgcactga ccctgtcctc ggccatgtgg ttctctggg gcgtcctgct  
 5 1981 caactccggc atcggggaag gcgccccag aagcttctca gcgcgcatcc tgggcatggt  
 2041 gtgggccggc ttgcatga tcatctggc ctctacacc gccaacctgg ccgtttcct  
 2101 ggtgctggac cggccggagg agcgcatcac gggcatcaac gaccctcggc tgaggaaccc  
 2161 ttctgacaag ttatctact ccacggtgaa gcagagctcc gtggatact acttccggcg  
 2221 ccaggtggag ctgagcacca tgtaccgga tatggagaag cacaactacg agagtgcggc  
 10 2281 ggaagccatc caggccgtga gagacaaca gctgcatgcc ttcatctggg actcggcggt  
 2341 gctggagttc gaggcctcgc agaagtgcga cctggtgacg actggagagc tgttttccg  
 2401 ctccggcttc ggcataggca tgcgcaaaga cagccctgg aagcagaacg tctccctgc  
 2461 catectcaag tcccacgaga atggcttcat ggaagacctg gacaagacgt gggttcggta  
 2521 tcaggaatgt gactcgcga gcaacgccc tgcgacctt acttttgaga acatggccgg  
 15 2581 ggtcttcatg ctggtagctg ggggcctcgt ggccgggac ttctgattt tcatcgagat  
 2641 tgcctacaag cggcacaagg atgctcgcg gaagcagatg cagctggcct ttgccgccgt  
 2701 taacgtgtgg cggaagaacc tgcagcagta ccatccact gatcacgg gcccgctcaa  
 2761 cctctcagat cctcgggtca gcaccgtgt gtgaggcccc cggaggcgcc cactgcccc  
 2821 gttagcccg ccaaggacac tgatgggtcc tgctgctcgg gaaggcctga gggaagccca  
 20 2881 cccgccccag agactgccca cctgggcct cccgtccgtc cggccgcca ccccgctgcc  
 2941 tggcgccacc ctgctggacc aaggtgcgga ccggagcggc tgaggacggg gcagagctga  
 3001 gtcggctggg caggggcgag gcgcgtgcac ggcagaggca gggcctgggg tctctgagca  
 3061 gtggggagcg ggggctaact ggcccaggcg gagggccttg gagcagagac ggcagcccca  
 3121 tccttccgg cagcaccagc gtgagggcca

25 SEQ ID NO: 39

Homo sapiens microtubule-associated protein tau (MAPT), transcript  
variant 2, mRNA.

ACCESSION NM\_005910 NM\_173727

(bases 1 to 2796)

30 ORIGIN

1 cctccccctgg ggaggtcgc gttcccgtg ctgcgcctg ccgccccgg gcctcaggaa  
 61 cgcgccctct cgccgcgcgc gccctgcag tcaccgccac ccaccagctc cggcaccaac  
 121 agcagcgccg ctgccaccg ccacctctg ccgcccgcac cacagccacc ttctctcct  
 181 ccgtgtcct ctccgtcct cgctctgtc gactatcagg tgaacttga accaggatgg  
 35 241 ctgagccccg ccaggagtgc gaagtgtgg aagatcacgc tgggacgtac gggttggggg

301 acaggaaaga tcaggggggc tacaccatgc accaagacca agagggtgac acggacgctg  
 361 gcctgaaaga atctccctg cagaccccca ctgaggacgg atctgaggaa ccgggctctg  
 421 aaacctctga tgctaagagc actccaacag cggaagatgt gacagcacc ttagtggtg  
 481 agggagctcc cggcaagcag gctgccgcgc agccccacac ggagatccca gaaggaacca  
 5 541 cagctgaaga agcaggcatt ggagacaccc ccagcctgga agacgaagct gctggtcacg  
 601 tgaccaagc tcgcatggtc agtaaaagca aagacgggac tggaagcga gacaaaaag  
 661 ccaagggggc tgatggtaaa acgaagatcg ccacaccgcg gggagcagcc cctccaggcc  
 721 agaagggcca ggccaacgcc accaggattc cagcaaaaac cccgcccgct ccaaagacac  
 781 caccagctc tggtaacct ccaaaatcag gggatcgag cggtacagc agccccggct  
 10 841 cccaggcac tcccggcagc cgctcccga ccccgccct tccaaccca cccaccggg  
 901 agccaagaa ggtggcagt gtcctactc caccaagtc gccgtctcc gccaagagcc  
 961 gcctgcagac agccccgtg cccatgccag acctgaagaa tgtcaagtc aagatcggt  
 1021 cactgagaa cctgaagcac cagccgggag gcgggaaggt gcagataatt aataagaagc  
 1081 tggatcttag caagctccag tcaagtgtg gctcaaagga taatatcaa cagtcgccg  
 15 1141 gaggcggcag tgtgcaaata gtctaaaac cagttgacct gagcaagggt acctccaagt  
 1201 gtggctcatt aggcaacatc catcataaac caggaggtgg ccagggtgaa gtaaatctg  
 1261 agaagcttga cttcaaggac agagtcagc cgaagattgg gtcctggac aatatcacc  
 1321 acgtccctgg cggaggaaat aaaaagattg aaaccacaa gctgacctic cgcgagaacg  
 1381 ccaaagccaa gacagaccac ggggcggaga tcgtgtacaa gtcgccagt gtgtctggg  
 20 1441 acagcttcc acggcatctc agcaatgtc cctccaccgg cagcatcac atggtagact  
 1501 cgccccagct cgccacgcta gctgacgagg tgtctgcct cctggccaag cagggtttgt  
 1561 gatcaggccc ctggggcgg caataattgt ggagaggaga gaatgagaga gtgtggaaaa  
 1621 aaaaagaata atgaccggc ccccgccctc tgccccagc tctcctgc agttcggtta  
 1681 attggttaat cacttaacct gctttgtca ctcggtttg gtcgggact tcaaatcag  
 25 1741 tgatgggagt aagagcaaat ttcatcttc caaattgat ggtgggctag taataaata  
 1801 ttaaaaaaa aacattcaaa aacatggcca catccaacat ttctcaggc aattccttt  
 1861 gattctttt tcttccct ccatgtagaa gagggagaag gagaggctt gaaagctgt  
 1921 tctgggggat ttcaaggac tgggggtgcc aaccacctt ggccctgtt tgggggtgt  
 1981 cacagaggca gtggcagcaa caaaggattt gaaaacttt gtgtttcgt ggagccacg  
 30 2041 gcagacgatg tcaacctgt gtgagtgtga cgggggttg ggtggggcgg gaggccacg  
 2101 gggaggccga ggcaggggt ggcagaggg gaggaggaag cacaagaagt gggagtggga  
 2161 gaggaagcca cgtgctggag agtagacatc cccctcctt ccgtgggag agccaaggcc  
 2221 tatccacct gcagcgtctg agcggccgcc tctccttgt gccgggggt gggggcctgc  
 2281 tgtgggtcag tgtccaccc tctcagggc agcctgtggg agaaggaca gcgggttaa  
 35 2341 aagagaaggc aagcctggca ggagggttg cacttcgat atgacctct tagaaagact

2401 gaccttgatg tcttgagagc gctggcctct tctccctcc ctgcagggtg gggcgctga  
 2461 gcctagggcg ttcctctgc tccacagaaa cctgtttta ttgagttctg aaggttgga  
 2521 ctgctgcat gattttggcc actttgcaga cctgggactt tagggctaac cagttctct  
 2581 tgtaaggact tgtgcctctt gggagacgtc caccgttc caagcctggg ccactggcat  
 5 2641 ctctggagtg tgtgggggtc tgggaggcag gtcccagacc cctgtcctt cccacggcca  
 2701 ctgcagtcac cccgtctgcg ccgtgtgtct gttgtctgcc gtgagagccc aatcactgcc  
 2761 tatacccctc atcacacgtc acaatgtccc gaattc

SEQ ID NO: 54

Homo sapiens troponin T2, cardiac (TNNT2), transcript variant 4,  
 10 mRNA.

ACCESSION NM\_001001432

(bases 1 to 1114)

ORIGIN

1 ccccgctgag actgagcaga cgcctccagg atctgtcggc agctgtgtt ctgagggaga  
 15 61 gcagagacca tgtctgacat agaagagggtg gtggaagagt acgaggagga ggagcaggaa  
 121 gagcaggagg aggcagcgga agaggatgct gaagcagagg ctgagaccga ggagaccagg  
 181 gcagaagaag atgaagaaga agaggaagca aaggaggctg aagatggccc aatggaggag  
 241 tccaaaccaa agcccaggtc gttcatgccc aacttggtgc ctccaagat cccgatgga  
 301 gagagagtgg actttgatga catccaccgg aagcgcatgg agaaggacct gaatgagttg  
 20 361 caggcgctga tcgaggctca ctttgagaac aggaagaaag aggaggagga gtcgtttct  
 421 ctcaaagaca ggatcgagag acgtcgggca gagcgggccc agcagcagcg catccggaat  
 481 gagcgggaga aggagcggca gaaccgctg gctgaagaga gggctcgacg agaggaggag  
 541 gagaacagga ggaaggctga ggatgaggcc cggaagaaga aggtttgtc caacatgatg  
 601 cattttgggg gttacatcca gaaggcccag acagagcggga aaagtgggaa gaggcagact  
 25 661 gagcgggaaa agaagaagaa gattctggct gagaggagga agtgctggc cattgaccac  
 721 ctgaatgaag atcagctgag ggagaaggcc aaggagctgt ggcagagcat ctataacttg  
 781 gaggcagaga agttcgacct gcaggagaag ttcaagcagc agaaatatga gatcaatgtt  
 841 ctccgaaaca ggatcaacga taaccagaaa gtctccaaga cccgcgggaa ggctaaagtc  
 901 accgggcgct ggaaatagag cctggcctcc ttcaccaaag atctgtcct cgtctgcacc  
 30 961 tgctccggc ctgcactccc ccagttccc ggccctctg ggcaccccag gcagctcctg  
 1021 ttggaaatg gggagctggc ctagggtgga gccaccactc ctgcctgccc ccacaccac  
 1081 tccacaccag taataaaaag ccaccacaca ctga

SEQ ID NO: 55

Homo sapiens troponin T3, skeletal, fast (TNNT3), mRNA.

35 ACCESSION NM\_006757

(bases 1 to 1000)

ORIGIN

1 cccaccttca ccatgtctga cgaggaagtt gaacaggtgg aggagcagta cgaagaagaa  
61 gaggaagccc aggaggaaga ggaagttcaa gaagacaccg cagaggagga cgcggaagag  
5 121 gagaaccga gacccaaact cactgtctct aagatcccag aaggggagaa agtggacttc  
181 gatgacatcc agaagaagcg tcagaacaaa gacctaattg agtccaggc cctcatcgac  
241 agccactttg aagcccggaa gaaggaggag gaggagctgg tcgtctcaa agagagaatc  
301 gagaagcgcc gtgcagagag agcggagcag cagaggattc gtgcagagaa ggagagggag  
361 cgccagaaca gactggcgga ggaaaaggcc agaaggagg aggaggatgc caagaggagg  
10 421 gcagaggacg acctgaagaa gaagaaagcg ctgtctcca tgggcgcca ctacagcagc  
481 tacctggcca aggctgacca gaagagaggc aagaagcaga cagcccgaga gatgaagaag  
541 aagattctgg ctgagagacg caagccgctc aacatcgatc accttggtga agacaaactg  
601 agggacaagg ccaaggagct ctgggagacc ctgcaccagc tggagattga caagttcgag  
661 ttgggggaga agctgaaacg ccagaaatat gacatcacca cgctcaggag ccgcattgac  
15 721 caggcccaga agcacagcaa gaaggctggg accccagcca agggcaaagt cggcgggagc  
781 tggaagtaga gaggccagaa aggccctcga ggcagagacc ctccgccctc ttgcacacca  
841 gggccgctcg tgggactcca catctccag cccccacaat cctgtcaggg gtctccctga  
901 cgtcctgggg gtggagaggc catccgggg cgteccccgc gtctgtgtcc ttgctgcctt  
961 cateccctgg ggctgtgaa taaagctgca gaacccctt  
20